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Introduction to the dissertation 
 
The concept of osteopathic healthcare is based on maintaining and re-establishing homeostasis 
within and in between body systems to support the body in the activation of its own innate 
capacity to heal. This philosophy incorporates the belief that unhindered flow of blood and 
lymphatic fluid is a prerequisite for human health. Osteopathic practitioners aim to locate and 
correct structural or functional changes in the tissues of the human body that may impair the free 
flow of blood and lymph (Degenhardt & Kuchera, 1996). The osteopathic profession has long 
been aware of the significance of the lymphatic system in health support and the Lymphatic 
Pump technique (LPT) is reported to have been utilized by osteopathic practitioners since the late 
nineteenth century (Hildreth, 1938; Millard, 1922; Parker, 1934; Still, 1899, 1902). 
 
LPT consists of rapid, rhythmic compressions over various lymphatic related tissues of the body 
and osteopaths refer to thoracic, abdominal, spleen, liver and pedal pump techniques (McMillan, 
Crow, & Greene, 2004). There are an abundance of osteopathic reviews reporting historical 
clinical cases supporting the efficacy of LPT (Amalfitano, 1987; Chikly, 2005) and in addition 
studies of the effect of LPT on lymphatic flow (Knott, Tune, Stoll, & Downey, 2005) or 
immunological markers in humans (Breithaupt et al., 2001; Jackson et al., 1998; J. W. Measel, 
Jr., 1982; J. W. Measel & Kafity, 1986; Noll et al., 2004) and animals (Hodge et al., 2010; 
Hodge et al., 2007; Schander et al., 2008), but to date there have been only three studies 
investigating clinical outcomes of LPT in humans and animals (Pedrueza, Zhang, Jones, & 
Hodge, 2010; Sleszynski & Kelso, 1993).  
The most active research in the area currently focuses on the reaction of immunological markers 
to LPT (McMillan et al., 2004). One product of the immune system, immunoglobulin A (IgA), is 
released from the B lymphocytes into the blood and also, uniquely among immunoglobulin, is 
secreted in immunologically relevant quantities into saliva, tears, breast milk and respiratory, 
nasal and vaginal mucosa (Wood, 2006). IgA antibodies are the body’s first line of defense 
against pathogens that enter via mucosal sites and act by immobilizing micro-organisms or 
preventing their attachment to mucosal surfaces. Salivary IgA is one of the easiest measurable 
immune markers and while concentrations are not necessarily an indication of health the 
literature appears to support the view that increased S-IgA levels may have a positive impact on 
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human health (Kaufman & Lamster, 2002; Latiff & Kerr, 2007). Decreased S-IgA concentrations 
are frequently associated with oral as well as systemic diseases. However, individuals with 
decreased S-IgA levels can present without any symptoms (Brandtzaeg, 2007).  
 
The primary purposes of this thesis were to review literature underpinning LPT and its 
theoretical and empirical effect on S-IgA in saliva as one output of the immune system and then 
to investigate the short-term effect of a brief lymphatic pump treatment on salivary S-IgA levels 
in a homogeneous population of asymptomatic participants. The investigation entails a single 
systems research design in which a salivary IgA baseline was established over 5 days with 
subsequent salivary samples before and after a 7 minute thoracic lymphatic pump treatment. S-
IgA level as the primary outcome measure was determined via enzyme-linked immunosorbent 
assay (ELISA). 
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Osteopathy and Health 
 
Modern osteopathy appears to have its scope of practice limited to the treatment of 
musculoskeletal problems, yet in the early days of the profession osteopathic practitioners were 
asked to treat numerous infectious diseases and were also utilized as primary health care 
providers (Stone, 1999; Ward, 2003). Retrospective data, collected after the 1918 influenza 
pandemic, suggest that lower morbidity and mortality amongst osteopathically treated patients as 
compared to those treated with the standard medical care that was available at the time (Kuchera 
& Kuchera, 1993).  
Osteopathic Philosophy and Dysfunction 
 
Osteopathic philosophy insists that for optimal function to be achieved the human body has to be 
integrated across all its interconnected body systems. In osteopathy, the term “function” implies 
an ideal structural and physiological state that allows each body component to work correctly 
and efficiently on its own and in relation to other body components (Kuchera & Kuchera, 1993; 
Stone, 1999) It is believed by the osteopathic profession that the development of disease is more 
likely if there is a disturbance in function. Therefore, osteopathic practitioners conclude that the 
underlying cause of disease is a breakdown of function of one or more body components and 
thus reestablishing function is the aim of treatment (Ward, 2003).  
Osteopathic Dysfunction in relation to the Immune System 
 
Osteopathic practitioners usually address the immune system by assessing and treating the 
lymphatic system so that restrictions are removed to restore free flow of lymphatic fluid, as the 
flow rate of lymph fluid within the lymphatic vessels is considered to be related to immune 
system function (Degenhardt & Kuchera, 1996). Decreased lymphatic flow causes tissue edema 
and accumulation of waste products and can interfere with cellular activity resulting in cell 
dysfunction and disease. Increasing lymph flow and drainage of lymph fluid out of tissues 
optimizes the transport and removal of inflammatory mediators (Degenhardt & Kuchera, 1996; 
Ward, 2003).  
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How can Osteopathic treatment influence the Immune System? 
 
Osteopathic practitioners seek to affect the functioning of those structures that are considered to 
be directly or indirectly related to immune function. Organs such as liver, thymus, spleen and the 
intestines, play an important role in the synthesis, neutralization and elimination of immune 
related cells and are treated either directly or by releasing of restricted tissues surrounding the 
respective organ (Ward, 2003; Wood, 2006). Structures associated with lymphatic flow such as 
lymph vessels and lymph nodes are not easily accessible and the osteopathic approach is again 
centered on treating restrictions in surrounding tissues through which those structures pass such 
as muscles and fascia. Fascia is a connective tissue that surrounds and connects internal 
structures throughout the body. Dysfunctional muscle or fascia hinders the movement of 
lymphatic fluid (Paoletti, 2006). Additionally osteopathic treatment utilizes a wide range of 
pumping and draining techniques. Osteopaths state that pumping and drainage techniques, 
applied over immune related tissues, can influence lymphatic flow by altering pressure 
relationships and providing suction effects (Guyton & Hall, 2000; Ward, 2003).  
In a broader sense, osteopathy also asserts that osteopathic intervention influences the immune 
system by aiming to return the body to a state of homeostasis. Homeostasis can be defined as the 
optimum physiological and structural balance and equilibrium within the body (St John, 1995). 
Any challenge to homeostasis triggers a stress response in the body with a subsequent release of 
stress related chemicals and hormones which affect the immunes system in numerous ways 
(Kuchera & Kuchera, 1993; Stone, 1999; Ward, 2003).  
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Overview of the Immune system 
 
Our environment contains numerous microorganisms that can cause disease in the human body. 
The ability of these organisms to evolve, change and enter the human body has to be met by a 
very adaptive immune system. Additionally, most cells in the body constantly renew themselves 
and tumor formation, caused by abnormal cell proliferation, has to be monitored and 
counteracted by the immune system. The enormous diversity of pathogens and the difficulty of 
destroying pathogens without damaging the host gives an indication of the complexity of the 
human immune system (Wood, 2006). 
 
The immune system of each individual reflects their genetics and past and present antigen 
challenges (Roit, Brostoff, & Male, 2001). Immune deficiencies may manifest without any 
symptoms - as often can be  the case in immunoglobulin A deficiency - or may cause minor or  
major health issues for example in HIV positive individuals that suffer from viral destruction of 
vital immune cells (Moore & Dalley, 1999; Pilette, Durham, Vaerman, & Sibille, 2004; Wood, 
2006). 
 
Challenges to the immune system are met by several levels of defense that are incorporated 
within either the innate or the cell mediated branches of the immune system (Wood, 2006). The 
development of topical infections on mucosal surfaces is opposed by the secretory or mucosal 
part of the innate immune system. Topical infections include those of the oral surfaces and the 
upper respiratory tract and are met by specialized mucosal cells including those which secrete 
salivary S-IgA (Woof & Kerr, 2006). The mucosal or secretory division of the immune system 
aims to neutralize pathogens before they can destroy healthy tissue or penetrate further into the 
body. Communication between mucosal immune cells and other immune system cells and 
components ensures further actions on pathogens that threaten to overpower the secretory 
defense (Roit et al., 2001). 
 
 
 
.  
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Components of the Immune system 
 
The lymphatic system, a network of lymph vessels, ducts and nodes that is also considered to be 
a part of the circulatory system, plays a large role in the transport and interaction of immune 
modulators (Albers et al., 2005; Chikly, 2005; Wood, 2006). The lymphatic organs are classified 
as primary or secondary. Primary lymphatic organs are the thymus, responsible for the 
development of T lymphocytes, and the bone marrow where the maturation of B lymphocytes 
takes place. Secondary lymphatic organs are the spleen, lymph nodes and mucosa associated 
lymphatic tissue (MALT) including gut associated lymphatic tissue (GALT) and nasal associated 
lymphatic tissue (NALT) (Roit et al., 2001) Additionally, almost all tissues and organs such as 
the brain, liver, kidney and lungs contain phagocytic cells. Phagocytes are cells that internalize 
and then destroy microorganisms (Brandtzaeg, 2007). 
 
The main feature of cell or antibody-mediated immunity is the ability of B lymphocytes to 
produce antibody-secreting plasma cells with specificity for a certain type of pathogen (antigen). 
After the initial infection has been eradicated, these cells can remain in the bloodstream as 
memory cells to protect against future infection from the same organism. In addition antibodies 
have a considerable half life ranging from ~ 6 days for IgA in secretions to ~ 3 weeks in the case 
of IgG in serum (Freitas, 2003). 
 
Antibody-mediated immunity is dependent on cellular action where T lymphocytes differentiate 
into T helper cells (Th). T helper cells promote the production of antibodies and control the 
ability of B-lymphocytes to express and produce different types of antibody classes. This 
immune function is known as antibody class switching (Wood, 2006). Protective antibodies can 
recognize, bind and neutralize antigen and activate immune mechanisms, such as agglutination, 
activation of complement and antibody dependent cytotoxicity, to destroy and eliminate 
pathogens. Agglutination decreases the spreading of pathogens by containing them in clumps. 
This process is made possible by the ability of antibodies to bind to more then one antigenic 
particle. Larger formations of pathogens are more easily recognized and destroyed. Some classes 
of antibodies have the ability to activate the complement system, resulting in the release of a 
complex cascade of molecules that aid in the destruction and clearance of pathogens. Antibodies 
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can also activate antibody-dependent cell-mediated cytotoxicity (ADDC) where immune cells 
are attracted to destroy an antigenic cell that is bound to the antibody (Roit et al., 2001; Wood, 
2006). 
 
All antibodies have a similar symmetric core structure comprising two heavy chains and two 
light chains usually depicted in a Y-shape(Figure 1). The heavy chains are linked to each other 
and to the light chains by disulphide bridges. A hinge region gives the molecule flexibility. The 
N-terminal domains are responsible for binding antigen and are also known as variable domains 
or variable regions since their amino acid sequences differ between antibodies to guarantee 
antigen specificity. The C-terminal domains form the Fc- portion of the molecule, necessary for 
recognition by the Fc-receptor on macrophages or natural killer cells (Wood, 2006; Woof & 
Kerr, 2006).  
 
The different functions of antibodies have given rise to five classes of antibodies: IgG, IgM, IgD, 
IgE and IgA with four subclasses of IgG and two of IgA. Different classes of antibodies can have 
the same antigen specificity (Pilette et al., 2004; Wood, 2006; Woof & Kerr, 2006).  
 
Figure 1: Antibody structure (Woof & Kerr, 2006) 
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Immunoglobulin A (IgA) 
 
IgA is a major serum antibody and is the main class of antibody found in secretions of mucosal 
surfaces. The two subclasses of IgA -IgA1 and IgA2- seem to have similar roles. One major 
difference between the subclasses lies in the hinge region which is more extended in IgA1 
indicating further reach between the two Fab arms of the molecule. Therefore IgA1 may be able 
to attach concurrently to two antigens that are separated by a considerable distance. IgA2 has 
greater stability based on increased resistance to certain proteases produced by bacteria (Pilette et 
al., 2004; Wood, 2006).Secretory IgA (S-IgA) is produced in the form of dimers constituting of 
two IgA monomers that are linked to one molecule of J (joining) chain and possess an attached 
secretory piece(Figure 2). The J chain is responsible for transport of IgA into secretions. The 
secretory piece protects IgA from breakdown by proteolytic enzymes that are present in 
secretions (Woof & Kerr, 2006). 
 
 
 
Figure 2: Dimeric serum IgA (on left) and Secretory IgA with attached secretory piece  
( on right) (Woof & Kerr, 2006) 
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Sites of IgA synthesis 
 
Serum IgA is synthesized by bone marrow plasma cells while secretory IgA(S-IgA) is the 
product of lymphocytes in various lymphoid and non-lymphoid tissues. The highly specialized 
mucosal immune system tissues such as GALT, MALT and Peyers patches functions largely 
independent of the systemic immune system (Czerkinsky, Svennerholm, & Quiding, 
1991).Following secretion by plasma cells into the mucosa,S-IgA binds to the poly-Ig 
receptor(pIgR) on mucosal epithelial cells. The pIgR/ S-IgA complex is then internalized by the 
epithelial cells where the poly-Ig receptor undergoes enzymatic cleavage to form the secretory 
component (SC) attached to the S-IgA molecule (Brandtzaeg, 2007).The secretory component 
acts as a receptor and transepithelial transporter for S-IgA. The subsequent secretion of S-IgA 
into the mucosal fluid involves partial proteolysis of the SC where one portion stays complexed 
to dimeric IgA and the remaining portion of SC is recycled by the epithelial cells. The SC 
connected to dimeric IgA protects it from proteolysis by microorganisms present on mucosal 
surfaces (Brandtzaeg, 1995; Mackinnon, 1999). 
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The secretory IgA (S-IgA) system 
 
The unique ability of secretory immunoglobulin for high antigen binding and their relative 
resistance to proteolytic destruction enables them to fulfill their role in the specific environment 
of mucosal surfaces. S-IgA, unlike the other immunoglobulins, has restricted ability to activate 
defense mechanisms that involve inflammatory processes, therefore preventing chronic 
inflammation in the mucosa (Brandtzaeg, 2003; Challacombe, Rahman, Jeffery, Davis, & 
O'Hagan, 1992). However, it has been shown that S-IgA can act as a potent stimulus for 
eosinophil activation. Eosinophils are involved in pro-inflammatory processes and allergic 
reactions (Brenner, Shek, & Shepard, 1994; Roit et al., 2001). 
 
The secretion of IgA is dependent on T lymphocyte interaction that initiates the differentiation of 
B lymphocytes into S-IgA antibody-producing plasma cells and later into memory cells that can 
provide a quick antibody response to later exposure to the same antigen. Antigen presentation at 
various lymphoid tissues then results in the migration of antigen-specific salivary IgA secreting 
plasma cells to the mucosal surfaces. 
However, there may be a T lymphocyte independent activation of S-IgA producing B 
lymphocytes (Wood, 2006). This, still not fully understood, process seems to be limited to the 
peritoneal cavity where macrophages release a substance that attracts B lymphocytes and may be 
crucial as part of a first line immune defense (Fagarasan & Honjo, 2004; Pilette et al., 2004). 
 
The association between the intestinal and salivary S-IgA response is at present not fully 
understood and studies investigating those connections show disparities. Although there is 
evidence that IgA secreting B-lymphocytes migrate from GALT to salivary glands it is now 
believed that NALT is more important as production site for B-lymphocytes destined for the 
salivary glands (Brandtzaeg, 2007; Corthesy, 2007). 
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Saliva as a diagnostic fluid 
 
Saliva analysis is presently used in the diagnosis of hereditary disorders, autoimmune disease, 
endocrine, infectious and malignant disease as well as for monitoring drug abuse. 
Saliva collection is non-invasive, pain free, simple, cost-effective for testing large populations 
and samples can be obtained by individuals without any specialized training. One of the 
disadvantages in saliva testing is the lack of standardization of the methods for saliva collection 
(Kaufman & Lamster, 2002; Lakshman, 2007; Mahvash & Satish, 2008).  
 
Whole saliva is produced by the three major salivary glands (parotid, submandibular and 
sublingual gland) and by the minor salivary glands that are present throughout the mouth. The 
minor salivary glands produce only about 10 percent of the fluid. The daily production of saliva 
ranges from 0.5 to 1.5 litres (Bokor-Bratic, 2000; Mahvash & Satish, 2008; Teeuw, Bosch, Enno, 
& Nieuw Amerongen, 2004). 
 
 The collection of gland specific saliva is possible  however, most routine studies collect whole 
saliva which is either stimulated via spitting or the use of citric acid, or non stimulated by passive 
drooling. (Mahvash & Satish, 2008). Saliva collection via spitting and drooling may prove to be 
problematic for reasons of social barriers, particularly in elderly individuals and the use of citric 
acid can interfere with immunoassay analysis as it decreases the pH of saliva (Groeschl, 2008).  
 
Commercially available collection devices are recommended to avoid contamination, however, 
absorbent collection pads have been known to absorb target molecules leading to false results 
(Groeschl, 2008; Michishige, 2006). For the calculation of saliva flow rates samples should be 
timed and weighed (Albers et al., 2005; Brandtzaeg, 2007; Kaufman & Lamster, 2002).  
 
Reported long term storage temperatures for saliva samples range from minus 20 degree  to 
minus 80 degree Celsius (Akimoto et al., 2003; McKune et al., 2005; Michishige, 2006; Pawlow 
& Jones, 2005) and it is advised to limit storage prior to freezing to a few hours at 4 degree 
Celsius (Salimetrics, 2009b).While it is unclear how differing storage temperatures may affect 
salivary S-IgA there is evidence that the length of storage time alters the S-IgA content in saliva 
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indicating that S-IgA concentration remains stable for up to 3 months at minus 30 degree Celsius 
and that increasing storage time then decreases the S-IgA concentration and the variability of the 
samples (Ng, Koh, Fu, & Chia, 2003). 
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S- IgA in saliva and its relation to health 
 
While S-IgA concentrations cannot be relied upon as an indicator of optimum immune system 
function, a number of lines of evidence support the view that there is an association between S-
IgA levels and health. Elevated salivary S-IgA levels observed in smokers have been interpreted 
as a reflection of the protection of the oral mucosa (Norhagen & Engstrom, 1998). Changes in 
salivary S-IgA have been linked to upper respirator tract infections, respiratory disease, dental 
caries and salivary S-IgA appears to play a role in the protection against HIV infection. For 
instance, several exercise related studies associate low levels of S-IgA with an increased 
incidence of upper respiratory tract infections(URTI) in elite athletes. While strenuous high 
intensity exercise is often associated with lower salivary S-IgA and subsequent URTI’s 
(Akimoto et al., 2003; Gleeson, Hall, McDonald, Flanagan, & Clancy, 1999; McKune et al., 
2005; Tharp & Barnes, 1990) it was found that moderate, regular exercise can increase salivary 
S-IgA levels in elderly subjects that have a higher risk of URTI based on their usually lowered 
salivary S-IgA levels (Akimoto et al., 2003). However, Akimoto (2003) and McKune (2005) did 
not use a control group. 
A study investigating immune markers in frequently ill children found that 94% of the 270 
participants had low levels of S-IgA (Markova & Chuvirov, 2007). Frequently ill children (FIC) 
were characterized as suffering acute respiratory diseases once every month with combined 
pathologies of the upper airways. The participants in this study were children aged 2-15 years 
and subsequently the results have to be evaluated under consideration of transient deviations and 
age related peculiarities of young immune systems (Roit et al., 2001). 
In an attempt to investigate the effect of increased S-IgA on upper respiratory tract conditions 
Kostinov et al.(2006) evaluated the influence of bacterial lysate on the mucosal immunity of HIV 
infected children. Lysate, a topical immuno-modulator; increased the synthesis of salivary S-IgA 
and this increase correlated with decreased inflammatory changes in the nasopharyngeal mucosa 
of the children (Kostinov et al., 2006). 
In vitro and in vivo research indicates that S-IgA can inhibit the adherence of bacteria to oral 
tissues and thereby protect against the development of gingivitis and caries (Teeuw et al., 2004) 
However, research investigating the relationship between S-IgA and oral health has produced 
conflicting data and inconsistencies are believed to relate to the fact that some species of oral 
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bacteria can render S-IgA ineffective (Lamm, 1997). At present it has not been firmly established 
what role salivary IgA has in the prevention of oral disease (Brandtzaeg, 2007; Teeuw et al., 
2004). 
 
In recent years, a specific mucosal immune response against human immunodeficiency virus 
type 1 (HIV-1) has been evaluated. An HIV-1 epitope recognized by IgA has been identified in 
HIV seronegative individuals that remained uninfected despite years of exposure to HIV infected 
partners. Salivary IgA from HIV-1-exposed, persistently seronegative (HEPS) subjects has been 
shown to neutralize HIV-1 and to block the transport of HIV1 across the epithelial barrier 
emphasizing the importance of mucosal immunity in the prevention of HIV infection (Bolscher 
et al., 2002; Devito, 2002; Teeuw et al., 2004). 
 
Secretory S-IgA is also believed to play a, still poorly understood, role in the maintenance of  
and in the return to local homeostasis and in the modulation and education of the mucosal 
immunity of the intestines and the airway mucosa (Pilette et al., 2004; Teeuw et al., 2004). 
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Mechanisms of the protective function of S-IgA in saliva 
 
S-IgA in saliva neutralizes enzymes, toxins and viruses and inhibits the adherence of bacteria to 
oral surfaces to prevent bacterial penetration of the mucosa. S-IgA neutralizes viruses by 
inhibiting the viral stages of fusion, attachment, internalization and replication. During its 
epithelial transport (transcytosis) S-IgA has the ability to bind viral proteins that are present in 
epithelial cells. This intracellular virus neutralizing ability is believed to be unique to S-IgA. 
However, the anti-bacterial and anti-viral effects of S-IgA in saliva are mainly derived from in 
vitro studies (Teeuw et al., 2004). Several bacterial strains have developed strategies to render S-
IgA ineffective and this fact may be responsible for some inconsistency amongst studies that 
investigated the antibacterial action of S-IgA (Michalek & Childers, 1990). 
 
In addition S-IgA fulfills its protective role by interacting with other antibacterial factors in 
saliva such as lysozyme, salivary peroxidase, cystatins, histatins and agglutinin. In the presence 
of IgA, possibly due to interactions of its Fc portion, the anti-streptococcal activity of 
lactoperoxidase is increased. S-IgA also intensifies the ability of lactoferrin to deprive 
microorganisms of iron and works in synergy with mucins to enhance the clearance of bacteria 
(Teeuw et al., 2004). 
.  
Induction and neuro-endocrine regulation of S IgA in saliva 
 
The response of S-IgA to oral antigen is believed to be generated by two processes. The first 
process, the local response, is the proliferation and differentiation of lymphoid cells into S-IgA 
producing B-cells in the submandibular, sublingual and parotid salivary glands following the 
stimulation by oral antigen. The second process, referred to as the common mucosal system, 
involves the movement of antigen activated B lymphocytes from MALT via the lymphatic 
system to the salivary glands where, upon entering the glandular tissue, the B lymphocytes 
mature under the influence of local T cells into S-IgA producing plasma cells (Teeuw et al., 
2004). Both processes underlie neuro-endocrine influences governed by the autonomic nervous 
system (ANS) and the hypothalamic-pituitary-adrenal axis (HPA) where the adrenal medulla, 
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acted upon by sympathetic neurons, presents as a specialized part of the ANS. Activation of 
these pathways results in elevated levels of cortisol and catecholamines including epinephrine 
and nor-epinephrine. Immune cells have receptors for these hormones (Bennet-Herbert & Cohen, 
1993). SNS related changes in immune response have been observed in the absence of altered 
cortisol levels suggesting that the SNS plays a greater role in immune alteration than the HPA 
axis. However, research suggests that glucocorticoids, and the female sex hormones estradiol and 
progesterone may increase gene expression of pIgR , the secretory component of S-IgA, 
therefore allowing for increased transport of S-IgA through the epithelial cells into saliva(Teeuw 
et al., 2004). 
The salivary glands are largely under control of the autonomic nervous system (Teeuw et al., 
2004).Autonomic stimulation also regulates distant immune cells, located in lymphoid tissues 
such as MALT, influencing antigen presentation, cell migration and production of antibodies 
(Bellinger, Lorton, Lubhahn, & Felten, 2001) and may also affect migration of IgA secreting B 
cells by vasoconstriction of blood vessels (Mackinnon, 1999). The increased S-IgA production 
that occurs during moderate exercise, which is a sympathetic stimulus, cannot be dampened by 
blocking alpha or beta adrenergic receptors (Ring et al., 2000; Winzer et al., 1999) and increased 
saliary IgA was noted in rats, following sympathetic (SNS) and parasympathetic nervous system 
(PSNS) stimulation of their salivary glands (Proctor & Carpenter, 2002). These findings 
underline that the sympathetic and parasympathetic branches of the autonomic nervous system 
do not work in an antagonistic manner and neural control of S-IgA synthesis, secretion and saliva 
production, although not fully understood, is synergistically influenced by both branches of the 
autonomic nervous system (Guyton & Hall, 2000; Teeuw et al., 2004).  
It is still not clear to what extent increased salivary S-IgA, following ANS stimulation, can be 
contributed to either an increased translocation of S-IgA across the epithelium of salivary glands 
or to an up regulated release by B lymphocytes (Bosch, Ring, De Geus, Veerman, & Amerongen, 
2002).  
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Measurement of secretory IgA in saliva 
 
S-IgA in saliva is most commonly measured by immunoassays that employ linking molecules 
labeled with reagents to detect antibodies or antigen. Immunoassays are economical in the use of 
reagents and very sensitive to the detection of antibodies (Roit et al., 2001). The enzyme linked 
immunosorbent assay (ELISA) utilizes an enzyme-linked antibody, bound to a solid support, 
such as a microtitre plate, that recognizes and binds to the immunoglobulin of interest. Following 
periods of incubation and rinsing to remove unbound immunoglobulin, a substrate that activates 
the enzyme is added. Bound antibody is quantified by the color change of the activated enzyme 
(Mackinnon, 1999). 
 
Salivary IgA is reported either as concentration in microgram per milliliter (μg/ml) or as 
secretion rate in microgram per minute (μg/min). Normal salivary S-IgA concentration in healthy 
adults ranges from 79.26 μg/ml to 679.50 μg/ml (Pawlow & Jones, 2005; Salimetrics, 
2009a).The salivary S-IgA secretion rate, reported in (μg/min), is suggestive of total S-IgA 
produced each minute and gives an indication of the availability of S-IgA on the mucosal 
surfaces (Mackinnon, 1999). The secretion rate is calculated by multiplying salivary S-IgA 
concentration by salivary flow rate (ml/min). The saliva flow rate is determined by dividing the 
amount of saliva sample by the time required to collect the sample (min) (Akimoto et al., 2003; 
McKune et al., 2005). In general it is recommended that salivary flow is not stimulated and that 
both, the absolute concentration and the secretion rate of S-IgA in saliva is reported (Akimoto et 
al., 2003; Brandtzaeg, 2007; Groer et al., 1994; Groeschl, 2008; Kaufman & Lamster, 2002; 
Salimetrics, 2009a).  
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Influences on secretory S-IgA levels in saliva 
 
Evidence exists that salivary S-IgA can be influenced by everyday activities including diet, 
exercise and stress levels (Albers et al., 2005). Several other variables may influence the level of 
antibodies in oral secretions such as sex, age, oral health, circadian influences, the impact of flow 
rate and protein loss during sample handling. In an ideal study all these factors should be strictly 
controlled. In practice not all factors can be controlled at the same time. Additionally, IgA 
deficiency and common variable immunodeficiency are conditions that may influence salivary S-
IgA (Albers et al., 2005; Brandtzaeg, 2007): 
IgA deficiency 
 
IgA deficiency is a relatively common finding and is usually not of immediate concern (Leman, 
2010). It is still a mystery why deficiency of the most copious molecule produced by a normal 
immune system is usually of such little consequence. However, IgA deficiency is associated with 
a greater risk of recurrent infections, food sensitization, neoplastic changes and autoimmune 
disorders (Barka et al., 1995; Koskinen, 1996; Pilette et al., 2004) and adverse reactions to blood 
transfusions (Eckrich, Mallory, & Sandler, 1993; Latiff & Kerr, 2007; Marwaha, 2006). 
 
IgA deficiency occurs in a primary or a secondary (acquired) form. Primary IgA deficiency with 
a prevalence of 1/500 to 1/2000 affects mucosal and serum IgA and presents as serum IgA level 
below 0.06g/L with normal serum IgG and IgM values (Latiff & Kerr, 2007). Discussion exists 
around the pathogenesis of primary IgA deficiency being either a failure of IgA class switch in B 
cells (Asano, Kaneko, & Terada, 2004; Brandtzaeg et al., 1999) or an inability of lymphocytes to 
differentiate into IgA secreting plasma cells (Cunningham-Rundles, 2001). Acquired, or 
secondary IgA deficiency, can be caused by the effects of drugs or infectious diseases (Latiff & 
Kerr, 2007) or by bone marrow transplants and blood transfusions from a deficient donor 
(Chandran, Khetan, Chaudhary, Misra, & Aggarwal, 2006; Marwaha, 2006) and while there have 
been spontaneous remissions it is considered to be a permanent condition (Latiff & Kerr, 2007). 
 
The reasons why IgA deficient individuals can remain asymptomatic are still not clear. However, 
the diagnosis of IgA deficiency is based on IgA concentration in serum and not in secretions. 
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Subsequently it is possible that individuals diagnosed with IgA deficiency may have enough 
secretory IgA in their mucosal system to offer some protective function (Leman, 2010). 
Additionally immune compensatory mechanisms may be present as healthy subjects with 
primary IgA deficiency show an increase in salivary secretory IgM and have a greater 
susceptibility for infections if their secretory IgM levels are low (Natvig, Johansen, Nordeng, 
Haraldsen, & Brandtzaeg, 1997). Yet, there is some doubt that secretory IgM grants the same 
protection then secretory IgA. In IgA deficient subjects the mucosal IgM defense against viruses 
appears to be less efficient than the IgA response in normal subjects and, following oral 
vaccination, IgA deficient blood donors were found to contain the poliovirus longer than normal 
subjects (Cunningham-Rundles, 2001). 
Disorders associated with IgA deficiency 
 
Regardless of the fact that most IgA deficient individuals are without symptoms, this 
immunodeficiency has a connection with certain diseases. Salivary S-IgA deficiency is 
diagnosed - with increasing frequency - in patients that suffer from allergies, recurrent upper 
respiratory tract infections, gastrointestinal diseases, malignancies and autoimmune diseases 
(Barka et al., 1995; Sarmiento et al., 2005).The autoimmune disorders most commonly 
associated with S-IgA deficiency include: systemic lupus erythematosus, rheumatoid arthritis, 
dermatomyositis, thyroiditis, celiac disease, Addison’s disease, inflammatory bowel disease, 
Sjoergrens’s syndrome, cerebral vasculitis, itiopathic thrombocytopenic purpura, and pernicious 
anemia (Barka et al., 1995; Cunningham-Rundles, 2001; Leman, 2010). 
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Common variable immunodeficiency 
 
Common variable immunodeficiency (CVID) is a hereditary defect, affecting either the 
production of antibody generating plasma cells or the immunoglobulin class switch from IgM to 
IgG (Blanco-Quiros, Solis-Sanchez, Garrote-Adrados, & Arranz-Sanz, 2006). CVID is related to 
primary IgA deficiency and both conditions can appear in the same family or evolve from one to 
the other in the same patient, therefore making differential diagnosis difficult (Espanol, Catala, 
Hernandez, Caragol, & Bertran, 1996; Vorechovsky et al., 1995). CVID is usually present at 
birth and clinical symptoms can manifest at any age but often only appear in adults. The 
symptoms vary greatly in their severity .Initial bacterial respiratory infections are -often years 
later- complicated by lymphoid hyperplasia, chronic lung disease and a large range of 
autoimmune processes (Sneller, 2001). 
 
Treatment of immunodeficiency 
 
For individuals diagnosed with common variable immunodeficiency at present the treatment of 
choice is Immunoglobulin G (Latiff & Kerr, 2007) therapy. For symptomatic IgA deficient 
patients the treatment is based on managing the associated diseases. Antibiotics are prescribed to 
control acute infections. Prophylactic antibiotics may be advised in cases of recurrent respiratory 
infections. Standard treatment is given for associated allergic or autoimmune disorders. In regard 
to the potential of anaphylactic reaction to blood transfusion it is recommended that the patient 
wears a medical alert bracelet. Education and awareness of the effects of hygiene, diet and 
lifestyle is also of importance (Blanco-Quiros et al., 2006; Latiff & Kerr, 2007; Leman, 2010). 
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Complementary Therapies and their effect on the immune system 
 
Numerous studies on alternative therapies including spinal manipulation (Brennan et al., 1991), 
self-hypnosis (Naito et al., 2003), relaxation (Hewson-Bower & Drummond, 1996) and massage 
have reported increases in immune related cells, among them salivary S-IgA, following the 
respective intervention. While it goes beyond the scope of this work to discuss all related 
research we recognize a need to focus on massage therapy as it represents another touch based 
therapeutic modality and appears to provide a number of clinical outcome studies with 
symptomatic subjects. Ironson et al.(1996), in a within subject single cohort study on 29 HIV 
positive participants, associated massage therapy with enhanced cytotoxic capacity of the 
immune system recorded as an increase in numbers of natural killer (NK) cells. Furthermore, a 
later randomized controlled study by Diego, Hernandez-Reif, Friedman and Ironson (2001) on 
24 HIV positive adolescents, receiving either massage or relaxation therapy, found that the 
massage group not only displayed higher numbers of NK cells than the relaxation group but also 
had increased CD4 numbers. CD4, a surface molecule on T cells plays a role in the resistance to 
viruses and the progression of AIDS is reflected by a reduction of CD4 (Roit et al., 2001). 
Similar findings are reported by Hernandez-Reif et al. (2005) in a study on woman diagnosed 
with breast cancer that received either massage therapy, standard cancer therapy or muscle 
relaxation technique. The massage group showed the greatest increases in NK cells and 
lymphocytes as compared to the other two groups suggesting a superiority of touch based 
modalities. The findings of these studies are strengthened by Arroyo-Morales, Olea, Ruiz, & De 
Dios Luna del Castilo (2009) who noted in their randomized, placebo controlled, single blinded 
study on 60 healthy subjects that massage therapy decreased the salivary cortisol and increased 
salivary IgA and total protein concentrations in the treatment group as compared to the sham 
group, after maximum effort exercise. They concluded that massage therapy may reduce the 
negative metabolic and immunologic effects of strenuous exercise.  
Conversely, a study by Eliska & Eliskova (1995) implies that massage therapy damages the 
peripheral lymphatic vessels. Massage therapy on men and dogs either with or without 
lymphedema (a pathological condition where fluid accumulates in the body’s tissues resulting in 
swelling) resulted, after only 3-5 minutes, in the destruction of lymphatics. The destructive 
effects were visible in the endothelial lining, the collagen and elastic fibers and also presented as 
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an accumulation of fibrous material, tissue debris and red blood cells in the walls of the 
lymphatic vessels. The limitations of these and other related studies are similar and include either 
small numbers of participants, lack of control group or difficulty in standardizing techniques, 
especially the pressure of strokes during massage therapy.  
 
Specifically immune related osteopathic techniques 
 
Osteopathic treatment addressing the lymphatic system is broadly divided into two categories: 
those techniques that aim to remove impediments to lymphatic flow and those that promote and 
enhance the movement of lymph fluid (Ward, 2003). Treatments that aim primarily to reduce 
blockages to lymphatic flow include Fascia Release treatment and Petrissage whilst treatments 
that are primarily aimed at improving lymphatic flow consist of Rib Raising, Diaphragm Doming 
and Lymphatic Pump techniques (Kuchera & Kuchera, 1993; Leman, 2010; Stone, 1999; Ward, 
2003). These techniques and their actions are outlined in Appendix D. 
 
Several other techniques, some based on mechanisms that are still disputed or not yet fully 
understood, claim to influence the immune system. These techniques include Chapman reflex 
treatment, Craniosacral Therapy and the Galbraith method (Chikly, 2005; Ward, 2003) 
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The lymphatic pump technique (LPT) 
 
Lymphatic pump treatment consists of a rhythmical pumping action applied to various immune 
related areas of the body to enhance fluid drainage and flow of lymphatic fluid Osteopaths utilize 
LPT to treat infection and edema. Several LPT’s exist including the thoracic pump, abdominal 
pump, spleenic pump, liver pump and pedal pump (McMillan et al., 2004) (Appendix D).The 
thoracic LPT utilizes a posterior and caudad force direction to elicit a gliding motion of the ribs 
around the costo-transverse joints, thereby rhythmically altering the diameter of the ribcage 
(Sleszynski & Kelso, 1993). 
 
 
 
Figure 1 The thoracic lymphatic pump (Sleszynski & Kelso, 1993) 
 
While the processes that enable LPT to enhance lymphatic circulation and protect against 
infection are not fully understood it is thought that the action of LPT mimics the respiratory 
effect on lymphatic ducts and nodes in that it changes the positive and negative pressure 
relationships between abdominal and thoracic cavity thereby producing a suction like effect that 
encourages flow of lymphatic and venous fluids into the thorax (Galewaler, 1969; McMillan et 
al., 2004). From here the two main lymph channels -the right and left thoracic duct- return the 
lymph fluid to the venous circulation (Guyton & Hall, 2000; McMillan et al., 2004). 
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LPT treatment and its effect on the immune system 
 
Research investigating and validating the immune enhancing effect of LPT is limited. Existing 
studies focus on three lines of investigation: The effect of LPT on the immune response, on 
lymphatic flow and on pathological conditions. 
 
Research on the effect of LPT on the immune response includes a small number of randomized 
controlled studies investigating the effect of LPT on antibody response to vaccination. Breithaupt 
et al. (2001), in a study on young and elderly populations, receiving daily post influenza 
vaccination LPT treatment over 4 days noted no significant changes between treatment (n=54) 
and control group (n=45) However, the authors provided evidence of improved general 
immunity and clinical outcomes, leading to the conclusion that LPT in conjunction with 
influenza vaccination may be of value in non-ambulatory patients or in at risk individuals that 
have had actual exposure to infection. 
Jackson et al. (1998) in a study on the effect of LPT on the antibody response to hepatitis B 
vaccine noted on average higher hepatitis B antibody titers in the treatment group (n=17-19) as 
compared to the control group (n=17-19) but reported the results of his study as inconclusive 
because of the small sample size and a wide variation in the antibody response. The outcomes of 
the Breithaupt (2001) and Jackson (1998) studies have to be considered in the light of unsimilar 
study populations and differing vaccination and treatment protocols however, they indicate a 
possible benefit of LPT in conjunction with vaccination.  
An older study by Measel (1982) examined LPT and the immune response of male medical 
students (n=25) after vaccination with pneumococcal polysaccharide. Two serological tests, 
bacterial agglutination and passive agglutination were employed to measure the impact on B cell 
and T cell components in the peripheral blood. By day 14 the treatment group (n=13), having 
received twice daily thoracic LPT, had a statistically greater humoral B cell immune response 
then the control group (n=12). The above study was repeated by the same author without the 
vaccination protocol in a randomly controlled double blinded manner on 21 medical students and 
the previous findings were confirmed (J. W. Measel & Kafity, 1986). The serological tests 
available at the time of these studies raise some doubt as to the reliability of the results and will 
hinder comparison with future studies on the same topic. 
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Research of poorer quality, including studies on animals, has looked at the response of immune 
mediator cells to LPT. Paul, Stomel, Broniak & Williams(1986) in an uncontrolled study on 12 
healthy subjects found no effect of LPT on interferon, a class of proteins that protect against viral 
destruction, whilst Mesina (1998) in a small controlled pilot study noted an increase in the 
percentage of basophils, white blood cells involved in inflammatory processes, following LPT on 
7 healthy male subjects. Numerous factors must be considered in the evaluation of those studies, 
including differing LPT protocols, small sample size, poor control and the difference in 
technology employed for performing the cell counts. 
 
Recent research on dogs demonstrated that LPT increases immune related cells in the lymphatic 
fluid of thoracic and intestinal lymph ducts. The study on 6 dogs by Hodge et al. (2010) found 
that LPT not only mobilized leukocytes (white blood cells), including macrophages, neutrophils, 
lymphocytes, T-cells and B-cells from the mesenteric lymph nodes (MLN) into lymph of the 
mesenteric and thoracic ducts but also increased lymphatic flow rate from 0.5ml/min to 2.7 
ml/min. Similar findings are reported by Huff, Schander, King, Downey & Hodge (2010) in a 
study on twelve dogs that investigated the effect of LPT on mobilization of inflammatory 
mediators into thoracic and intestinal duct lymph. Comparing baselines, during treatment and 
post treatment lymph samples and their concentration of various cells that are involved in the 
inflammatory process showed that the greatest increase had occurred in the concentration of 
interleukins (IL), especially IL-4, IL-6, IL 8, IL 10, IL 15. These proteins control aspects of the 
immune response including antibody synthesis. While the results of these studies may provide 
scientific rational for further research of LPT treatment they have to be interpreted cautiously. 
Animal research results are not always transferable to humans (Suvorov & Takser, 2008) and, in 
order to execute LPT on catheterized animals, the technique has to be modified and does not 
conform with LPT as performed on a human patient in a clinical situation (Knott et al., 2005). 
Research that evaluates the effect of LPT on lymph flow has been conducted solely on animals. 
Knott et al. (2005) demonstrated that thoracic and abdominal pump treatment increased lymph 
flow through the thoracic ducts of five dogs. Similar increases were also reported in the above 
mentioned study by Hodge (2010) in which flow rate in dogs increased from 0.5 to 2.7 ml/min. 
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Interestingly, in the study by Hodge (2010), the effects of the lymphatic pump treatment on 
lymph flow occurred without changes to mean arterial pressure, heart rate or cardiac output 
supporting the notion that LPT treatment has a primary influence on the lymphatic system. 
 
The effect of LPT on pathological conditions has not been researched extensively. While historic 
information from the 1918 Spanish influenza pandemic suggests a high success rate of 
osteopathic treatment (consisting primarily of LPT) reporting a mortality rate of 0.25% for a total 
of 110120 influenza patients under the care of osteopathic doctors (Smith, 1920) it has to be 
considered that the data of these uncontrolled studies with their unknown populations was 
collected retrospectively (Hruby & Hoffman, 2007). 
In a more recent study Sleszynski & Kelso (1993) compared thoracic LPT with incentive 
spirometry in the prevention of postoperative atelectasis, a collapse of the lungs and the most 
common cause of abdominal postoperative morbidity and mortality (Susini, Sisillo, & Bortone, 
1992). Incentive spirometry (IS) is a sustained maximal inspiratory maneuver commonly taught 
to patients to prevent atelectasis (Ros, Vincent, & Kahn, 1981). In this 1 year randomized 
researcher blinded trial, cholecystectomy (gall bladder removal) patients received either thoracic 
LPT (n=21) or IS (n=21) and Atelectasis occurred in 2 (5%) patients of each treatment group, 
possibly demonstrating that either treatment was equally effective. However, patients treated 
with thoracic LPT had an earlier recovery from surgery and showed a quicker return to pre-
operative values for lung capacity. The main limitation of this study is the lack of a placebo 
group due to ethical reasons. Other factors that limit the conclusions that can be drawn from this 
study are the small sample size, the restriction to only one institution and the low atelectasis risk 
status of the participants. 
In the osteopathic profession metastatic cancer is usually regarded as contraindication for certain 
osteopathic manipulative techniques including LPT. However, a recent controlled study 
conducted on rats demonstrated that LPT can reduce solid tumors in the lung tissue of rats. 
Pedrueza, Zhang, Jones, & Hodge (2010) subcutaneously injected laboratory rats with tumors 
that metastasize to the lungs. Following the injection the rats received four minutes LPT daily for 
seven days. A control group received no treatment while a sham group was treated with 4 
minutes of light touch. The results demonstrated a 30% reduction in pulmonary tumors in the 
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LPT group compared to sham and control group and, contrary to common believe, there was no 
distribution of tumor cells from the lungs into other tissues following LPT.  
While existing research on LPT appears to suggest that LPT can influence certain aspects of 
immunity, the transient nature of the benefits of LPT has been noted in several studies, leading to 
the necessity of further investigation in regards to the decay of immune markers and as to 
considerations and adjustments in the application protocol of LPT (Hodge et al., 2010; Huff et 
al., 2010; Knott et al., 2005)  
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Methodology 
 
Research and its documentation are crucial factors in the growth and acceptance of any 
profession and the need for experimental research is well recognized within the osteopathic field 
(Moran, 2005). 
While group designs, such as randomized controlled trials, are regarded as the gold standard of 
experimental research within evidenced based practice, they are often inappropriate for 
preliminary investigations and the logistics of this type of research requires resources that are not 
easily available within the osteopathic profession. Group designs are limited in their suitability 
for certain types of conditions and have been criticized for lacking transferability to individuals 
by representing only an average of the response to any given intervention (Sanders, 2003).  
Single systems research design (SSRD) provides a simple, economical way to evaluate treatment 
intervention and its effect on individual patients. In single systems research multiple 
measurements are recorded allowing for a more detailed assessment of the reaction to the 
treatment. This is particularly suited to osteopathy in its attempt to adept treatment to individual 
presentation. Single systems research also plays a vital role in building up a body of acceptance 
and knowledge around a certain intervention to justify further research utilizing more recognized 
and involved designs (Joshi, 2000). 
Immunological research generally requires large resources making single systems design a cost-
effective solution particularly for the investigation of emerging or little researched topics.  
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Research question 
 
Osteopathic practitioners commonly utilize LPT in their clinical practice to improve the 
functioning of their patients’ immune system although there is limited research to support their 
claim. Salivary IgA is an immune marker that plays a role in the maintenance of mucosal 
immunity and it is believed that decreased salivary S-IgA is responsible for the susceptibility to 
URTI’s. Secretory IgA in saliva is one of the more easily measured outputs of the immune 
system rendering its investigation suitable for a student project with limited funds. These 
considerations lead to the following research question: Does the osteopathic lymphatic pump 
technique (LPT) influence the secretory IgA levels in saliva of healthy subjects? 
 
Conclusion 
 
LPT is a widely used osteopathic technique that is often part of treatment sessions and is 
therefore financially supported by patients and by the government. It seems imperative to build 
up the body of knowledge around this technique. Salivary IgA, a major output marker of the 
immune system, is considered as a promising and worthwhile biological marker. Although the 
implications of salivary IgA for health and immunity are not yet fully established and understood 
the importance of salivary S-IgA for the health of the upper respiratory tract in athletes and in the 
elderly is repeatedly reported in the literature. At present no studies have investigated the 
influence of LPT on salivary S-IgA. It appears that further research into this topic is warranted 
and may provide a simple and cost effective means for the prevention and the treatment of 
infection in humans. 
To the author’s knowledge, at the time of submission, the research presented in this thesis may 
be the first and only single systems design study that investigates immunological markers in 
response to osteopathic intervention. 
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ABSTRACT 
 
Background:The osteopathic lymphatic pump technique (LPT), a treatment that has not been 
researched extensively, is widely used within the osteopathic profession to improve health in 
patients. Secretory immunoglobulin A (S-IgA) in saliva is related to mucosal immune system 
function and high levels of salivary S-IgA have been shown to decrease the incident of upper 
respiratory tract infection (URTI). The aim of this pilot study was to determine changes in 
salivary S-IgA in response to LPT.  
Design:A single systems research design using a modified A-B-C protocol on eight healthy male 
participants was used to evaluate the outcome measure defined as change in salivary S-IgA 
secretion rate (μg/ml) as determined by Enzyme Linked Immuno-Sorbant Assay (ELISA). 
Methods:Baseline measures of salivary S-IgA were recorded once daily over 5 days. On Day 5 a 
seven minute thoracic LPT treatment was administered immediately following the pre-treatment 
measurement. Two post-intervention measurements, at 1 minute post-treatment and at 10 minute 
post treatment were reported. 
Results: Visual analysis of the plotted outcome measures showed a short term increase in 
salivary S-IgA secretion rates following LPT in seven out of eight healthy male subjects. The 
averaged post-treatment measurements of salivary S-IgA secretion rates were higher when 
compared to the mean baseline (ES=3.0; p=0.03). Limited data points, lack of control and high 
variability of data weaken the study and make it difficult to conclude confidently that the 
intervention caused the results. 
Conclusion: The results of this study suggest that thoracic LPT may influence the salivary S-IgA 
levels in healthy males. Further research in this area seems to be warranted and may include a 
more robust research design with a larger sample size and inclusion of participants that suffer 
from mucosal immune compromise. 
 
Key Words: Immune system, Osteopathic treatment 
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INTRODUCTION 
 
There is a growing interest in finding and developing techniques that could boost the immune 
system. Besides the possible therapeutic value in situations of compromised immunity, such 
studies might further our understanding of the complex interactions between the function of 
immune parameters and physical therapy. 
One such technique, the osteopathic lymphatic pump technique (LPT) is widely used by 
osteopathic practitioners and is reputed to have a beneficial effect on the immune system by 
relieving lymphatic stasis and by enhancing the immune response.1, 2 
The clinical efficacy of LPT has been reported since the influenza pandemic in 1918. LPT was 
used to treat victims of the flu epidemic and the mortality amongst those treated fell to 0.25 
percent as compared to a 5 percent mortality rate in patients that did not receive the LPT 
treatment.3 More recent research found that LPT may prevent the occurrence of atelectasis 
following cholecystectomy4 and there is evidence that LPT increases immune related cells such 
as basophils5 and B-and-Tcells6 in peripheral blood. Other lines of research investigated the 
effect of LPT on antibody production following antigen exposure or vaccination. Measle7 
discovered that antibody production in response to introduced antigen such as pneumococcal 
poly-saccharide was increased in healthy males that received LPT however, some controversy 
exists in the effect of LPT on antibody production following vaccination. Jackson8 reported an 
enhanced immunological response to Hepatitis B vaccine in elderly individuals while Breithaupt1 
found no changes in antibody synthesis in response to influenza vaccination in elderly subjects. 
The latest evidence from animal studies links LPT to the mobilization of inflammatory mediator 
cells into the lymphatic ducts,9, 10 to increased flow of lymphatic fluid within the thoracic duct9, 11 
and to a reduction in the size of pulmonary tumors in rats.12 
While a number of studies have looked at the effect of LPT on various outputs of the immune 
system, to date no work has specifically investigated the influence of LPT on the mucosal 
immune response despite it being the first line of defense of the immune system.13, 14 Secretory 
Immunoglobulin A (S-IgA) in saliva is a relatively easily measured product of the mucosal 
immune system and is considered to be a major factor in determining the resistance to mucous 
membrane infection.15, 16 Low levels of salivary IgA have been reported in connection with 
dental caries15 and may present a risk of an increased susceptibility to upper respiratory tract 
infections in athletes16 and in the elderly.17 There appears to be a call to increase the knowledge 
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base around LPT and its effect on immune markers to support the osteopathic profession in the 
development and improvement of suitable treatment for patients with compromised immune 
health. 18 
Any investigation of the immune response to manual intervention involves extensive methods 
requiring monetary resources making it necessary to initiate preliminary trials prior to investing 
large amounts into group studies. The aim of this pilot, single systems study was to investigate if 
the osteopathic lymphatic pump treatment has any influence on the secretory immunoglobulin A 
(S-IgA) in the saliva of healthy male individuals. 
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METHODS 
Design 
 
This pilot study followed a modified A-B-C single systems research design19 to examine the 
effect of LPT on the S-IgA levels in the saliva of eight healthy male subjects. Phase A 
constituted of a five day baseline period with one daily saliva sample collection. During this time 
no treatment was given. Phase B was a seven minute LPT intervention administered on Day Five 
immediately after the last baseline saliva sample collection. The duration of the LPT treatment 
was based on previous studies 1, 3 and on the most common LPT treatment length in a clinical 
setting.  
Phase C consisted of two post intervention saliva samples, one sample immediately after the 
intervention and one 10 minutes post treatment. The short post-intervention intervals were 
chosen to minimize the effect of external influences on salivary IgA. Due to pragmatic 
considerations the post intervention data points had to be restricted to two measurements only. 
The study was conducted in a room on the premises of Unitec Auckland, Carrington Campus. 
The research protocol was approved by the Unitec Ethics Committee, Unitec, Mt Albert, New 
Zealand (Appendix A). 
Eligibility Criteria 
 
Subjects were recruited by poster advertisement at the Unitec Campus site. To be eligible for 
inclusion in the study the participants had to be healthy, male aged between 18 and 40 years and 
non-smokers. 
Male subjects were recruited to avoid hormonal variations of S-IgA during the female menstrual 
cycle.20 The lower age limit was determined to prevent legal and ethical under age issues with 
minors and the upper age limit was established to decrease the likelihood of age related 
influences on the immune response.22-24 The inclusion criteria of non-smoking was specified to 
limit the influence that smoking has on S-IgA concentrations.21 
Potential participants were not eligible to partake in the study if they presented with any of the 
following: 
• present oral infections  
• a history of cancer 
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• any autoimmune conditions including recent organ transplants  
• intake of medication that affects the immune system such as antibiotics and steroids  
• involvement in drug or alcohol abuse  
• thorax conditions that are contraindicated for LPT including rib fractures, pacemaker, 
recent thoracic surgery 
• an inability to understand and write the English language 
To screen for inclusion and exclusion criteria prospective participants were asked to complete a 
short questionnaire (Appendix B). 
Procedures 
 
Data were collected over a 5 day period from 14th – 18th of September 2009. The study protocol 
was explained to all eligible participants by the study organizer. Each participant received a 
written information sheet and had the opportunity to ask questions before verbal and written 
informed consent was obtained (Appendix A). 
Participants were asked to refrain from eating, drinking alcohol and exercising, all of which can 
influence salivary S-IgA levels, 19, 21, 26, 27 one hour prior to each saliva sample collection. 
Baseline saliva samples were collected on 5 consecutive days. To minimize circadian influences 
on S-IgA concentration sample collection took place at the same time each day 28, 29.Weight and 
height of each participant was recorded on day one.  
On arrival each participant rinsed their mouth with water and was asked to complete a short 
questionnaire to determine the presence of factors that may have influenced S-IgA production in 
the 2 hours prior to saliva sampling (Appendix B). 
The saliva collection via passive drooling of non-stimulated whole saliva into pre-weighed 2 ml 
snap-lock tubes was timed and the collection time was recorded by each participant on a 
prepared sheet (Appendix C). Each sample was collected in duplicate, labeled and recorded 
(Appendix C). The filled tubes were weighed and immediately frozen at the recommended 
storage temperature of minus 20 degree Celsius.22 On Day Five the final baseline saliva sample, 
which also acted as the pre-intervention sample, was followed immediately by a 7 minute 
thoracic LPT treatment administered by a qualified osteopath. Thoracic pump was chosen over 
other pump techniques as it is applied in close proximity to the salivary glands and has been the 
most commonly used lymphatic pump technique in previous studies 1, 6. The participant was 
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guided into an adjacent room and asked to recline on a treatment table. To perform the LPT the 
practitioner’s hands were placed on the clothed torso, bilaterally below the clavicles, with fingers 
pointing towards the subject’s feet and fanning out across the anterior and lateral aspects of the 
chest. Rhythmic pumping was applied at a rate of 50 - 60 pumps per minute for duration of seven 
minutes 8(Figure 1). Directly after the LPT intervention each participant provided the first post- 
treatment saliva sample following the saliva sampling routine as outlined above. The participant 
was then directed to sit quietly while reading a selected textbook chapter. A second post 
treatment sample was collected following 10 minutes of quiet sitting and reading. 
 
 
Figure 2Thoracic Pump (Jackson et al. 1998) 
Assays 
Salivary S-IgA competitive assay kits were purchased from Salimetrics (Salivary Secretory IgA 
Indirect Enzyme Immunoassay Kit, Catalog no.1-1602; 96-Well Kit.). 
Salivary S-IgA concentration (μg/ml) was determined with the ELISA technique which uses a 
horse radish peroxidase conjugated to goat anti-human S-IgA as the detecting antibody 27, 28. 
Laboratory analysis took place at the Unitec Faculty of Social Health Science laboratory. 
Laboratory conditions and procedures adhered to the recommendations provided with the test 
kits (www.salimetrics.com). 
Saliva samples were thawed on crushed ice, vortexed and centrifuged at 1500 x g (=3000rpm) 
for 15 minutes. The saliva volume was established by weight, assuming a specific gravity of 
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one.27 All samples were analyzed in duplicate (Appendix E). Assay analysis and generation of a 
standard curve (R² = 0.999) was performed with KC junior software (Bio-Tek Instruments 
Incorporated, 2002). 
 
Data Management and Analysis 
 
Raw data were compiled, checked for errors and manipulated using Microsoft Excel version 
2003. Statistical analysis of group data was performed with Statistical Package for the Social 
Sciences version 15 (SPSS Inc, Chicago, Illinois). Mean and standard deviation for the 
duplicates of salivary S-IgA concentration was calculated (Appendix E). 
Duplicates for Salivary S-IgA concentration were averaged and presented as absolute 
concentration of salivary S-IgA(μg/ml) and as salivary S-IgA secretion rate (μg/min). The 
secretion rate reflects the total amount of S-IgA arising on the mucosal surface per time unit and 
is calculated by multiplying the absolute S-IgA concentration by the saliva flow rate 
(ml/min).The saliva flow rate is obtained by dividing the amount of saliva in each sample (ml) 
by the time it took to produce the sample (min)2217(Appendix E). 
 
Data analysis for single systems research design (SSRD) is traditionally based on visual analysis 
of graphed individual data to depict whether the level or trend in the plotted data during the 
intervention phase shows a visually detectable difference from the level or trend of the baseline 
data.19, 23For individual data analysis graphs were constructed displaying S-IgA concentration, 
flow rates and secretion rates at baseline and following the treatment intervention. Evaluation is 
by visual inspection to identify trends in the baseline and post intervention phase and to assess 
changes in level of magnitude between phases. 
Group means were compared using analysis of variance (ANOVA) for multiple time points and a 
paired t-test to compare pre-and post-treatment measures. 
To evaluate the clinical significance group and individual effect sizes were calculated 
and interpreted based on Cohens “d” formula.24 The baseline standard deviation acted as the 
denominator as is recommended for studies with differing standard deviations between groups25 
and small numbers of baseline observations.26 When calculating effect sizes for SSRD data the 
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baseline data are treated as a control group and the intervention data acts as the experimental 
group.23 
RESULTS 
 
Eight asymptomatic participants completed the study. The age, weight and height of each 
participant is shown in Table 1. 
 
Table 1: Participant demographics 
 
Participant  Age Weight/kg Height/cm 
1 36 99 183 
2 25 78 168 
3 38 90 187 
4 22 82 180 
5 21 75 183 
6 26 65 173 
7 22 82 185 
8 39 70 176 
 
 
Individual data  
 
The data for salivary S-IgA for each participant’s concentration, flow rates and secretion rates is 
shown in Figure 1. The normal range of salivary S-IgA concentration is 79.26 to 679.50 μg/ml.27, 
30 The lines between data points on the individual graphs are omitted to avoid the impression of 
continuity of the S-IgA data between measurement readings. 
 
Visual inspection of the salivary S-IgA flow rate/concentration graphs for each participant show 
large variations within and between participants with no discernible trends during baseline or 
after treatment. All readings for individual participants’ pre- and post- treatment are within 
expected normal range for asymptomatic adults. An extreme flow rate  is noted for participant 3 
on Baseline Day 3. All participants showed an immediate post-treatment short-term increase in 
salivary S-IgA concentration when comparing the Baseline Day 5 to the Post-treatment 1 
measurement. However, when the flow rate is taken into account, this pattern is not consistent 
and salivary S-IgA secretion rates vary between participants.  
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Visual inspection of the individual salivary S-IgA secretion rates during baseline and 
intervention phases shows variable baseline with no obvious trend or pattern for participants 1, 3, 
5, 6, 7 and 8. For participants 2 and 4 there is a decreasing and an increasing trend respectively 
across baseline and both post-treatment phases. 
 
The 1 minute post-treatment measurement of the salivary S-IgA secretion rate shows an increase 
for all participants except one (participant 2). The 10 minute post-treatment measurement shows 
a further S-IgA secretion rate increase in two participants (3 and 4) while all other participants 
have a decreased S-IgA secretion rate at 10 minute post-treatment measurement (Figure 1). 
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Figure 3: Individual salivary S-IgA concentration, flow rate and secretion rate 
Column A:osaliva flow rate, x salivary S-IgA concentration, 1st y-axis S-IgA concentration (μg/ml), 
2nd  y-axis saliva flow rate (ml/min). Column B: x represents salivary S-IgA secretion rate, y-axis salivary S-
IgA secretion rate values (μg/min)(derived by multiplying S-IgA concentration and saliva flow rate). 
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Individual effect sizes for salivary S-IgA secretion rate measured as mean for Post Treatment 1 
and 2 in relation to Baseline mean ranged from moderate to large in all participants except one 
(participant 2). The decrease of S-IgA secretion rate for participant 2 is expressed as a negative 
effect (Table 2) 
 
 
Table 2:Individual salivary S-IgA secretion rates baseline and post-treatment means and effect sizes 
 
 
Subject Baseline 
mean 
μg/min 
Post-treatment 
1+2 mean 
μg/min 
Effect size 
1 73.42 124.69 1.1 
2 154.78 82.56 -0.8 
3 116.66 348.71 2.5 
4 95.77 365.14 4.9 
5 50.30 106.24 1.8 
6 67.41 155.72 2.3 
7 92.61 302.97 2.1 
8 144.19 202.30 3.6 
 
 
Group data 
 
The group data for Baseline, Post-Treatment1 minute and Post-Treatment 10 minute show means 
±  95% confidence interval. The effect size for Baseline to Post-Treatment 1minute was d=2.1. 
Mean effect size for baseline to post-treatment 10 minute was d=1.3 (Figure 3).  
Because the single systems analysis showed considerable non-systematic day-to-day variability 
in IgA at baseline, the group baseline data were calculated as the mean of the sum of the 
individual mean baseline values. There were no differences in salivary S-IgA secretion rate from 
mean baseline levels when the two post-treatment measurements were considered separately 
using repeated measures ANOVA. However, because underlying day-to-day variability in S-IgA 
might also apply to measurements taken 10 minutes apart, a paired t-test between mean baseline 
and mean post-treatment measurements was also conducted to test this. Post-treatment IgA levels 
when averaged were significantly higher than baseline levels (Effect size ES = 3.0; p=0.03). 
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Figure 4: Salivary S-IgA secretion rates μg/min (mean ± 95% CI) NR = normal range of S-IgA  
The baseline mean value was derived from all baseline samples collected over five days across  8 
participants (=40 samples). The 1 minute and 10 minute post treatment mean values are each derived from 8  
participants 
 
59 
 
DISCUSSION 
 
Overview 
 
Despite the common use of lymphatic pump technique (LPT) by osteopoathic practitioners in the 
treatment of immune-related conditions, research to validate the therapeutic effect of this 
technique on immune health is limited. Secreted Salivary Immunoglobulin A (S-IgA) is a 
relatively easily measured output of the immune system. While it is still unclear to what extent 
salivary S-IgA can be regarded as an indicator of immune health there is growing evidence that 
increased levels of salivary S-IgA may represent enhanced mucosal immune function and 
protection and that low levels of salivary S-IgA can reflect immune compromise. The aim of this 
pilot study was to observe any short-term influence of the lymphatic pump treatment (LPT) on 
the secretory immunoglobulin A (S-IgA) levels in the saliva of healthy male participants. 
 
Findings 
 
This study shows an immediate post-treatment increase in salivary S-IgA secretion rate in seven 
out of eight participants with moderate to large individual effect sizes suggesting there may be a 
high likelihood of a clinical significance. 23, 24 According to Hopkins27 effect sizes of this 
magnitude are likely to be therapeutically beneficial. True therapeutic benefit would need to be 
confirmed by comparing changes of this magnitude to changes in symptoms such as infection 
rates. However, one participant had moderately decreased salivary S-IgA secretion rates for both 
post-treatment measurements. The salivary S-IgA secretion rates at 10 minutes post-treatment 
varied, showing a further increase in two participants but a decrease for all other participants, 
underlining the transience and the individual nature of salivary S-IgA responses commonly 
observed in studies of salivary S-IgA.11, 28 Despite inconsistent flow rate patterns, within and 
across participants, the immediate post treatment S-IgA concentration increased for all 
participants when compared to the pre-treatment measurement. A comparison of mean group 
values for saliva S-IgA secretion rate baseline and combined post-treatment was statistically 
significant. These results, in conjunction with the general lack of studies in this area, may 
provide a basis for further research utilizing group designs and larger samples. 
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Interpretation of findings 
 
Whilst the group means show significant increases in salivary S-IgA from pre –treatment to post-
treatment, this needs to be interpreted carefully for reasons related to the limitations of this study 
that are discussed later. The patterns that we observed were not uniform across all participants 
and highlight the usefulness of looking at individual data in small pilot studies such as this. For 
instance, participant 2 appeared to have a consistent decrease in salivary S-IgA levels starting 
from mid baseline and extending to both post-treatment measurements. However, when 
surveying the reported health data of participant 2, it transpired that he had reported flu like 
symptoms for each day of the study period suggesting the likelihood of mucosal inflammation.29 
Activation of the mucosal immune response and binding of salivary S-IgA to invading 
microorganisms decreases the amount of unbound salivary S-IgA and may present one 
explanation for the results of this participant.30 However, recent research has also linked salivary 
IgA, previously regarded as a non-inflammatory immunoglobulin, to the activation of 
eosinophils in the mucosa.31 It has been proposed that salivary S-IgA is the principle 
immunoglobulin associated with mucosal eosinophils in the mediation of inflammatory diseases 
such as atopic disease and parasitic infection.32 With these mechanisms in mind, we suggest that 
the attachment of salivary S-IgA to mucosal eoosinophils could provide another explanation for 
the suppressed salivary S-IgA measurements in this participant. We would recommend that 
future salivary S-IgA research protocols consider excluding participants with any flu-like 
symptoms. 
 
To evaluate the observed patterns in this study it is necessary to consider the effect of saliva flow 
rates on the salivary S-IgA secretion rate. The salivary S-IgA secretion rate is a function of 
absolute immunoglobulin concentration and saliva flow rate and it represents the total amount of 
S-IgA available on the mucosal surface and therefore could be considered a more appropriate 
indicator of mucosal immune health.27, 39, 40 The need to measure flow rates for the calculation of 
salivary S-IgA secretion rates has been questioned in earlier studies.33 Jemmott and Magloire34 
investigated the relationship between academic stress and either salivary S-IgA concentration or 
S-IgA secretion rate and found both equally influenced by academic stress. At present it is 
recommended to calculate the salivary S-IgA secretion rate in order to determine if elevated 
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levels are caused by increased synthesis of salivary S-IgA or by changes in saliva flow rates.39, 
4320 
 
To calculate saliva flow rates it is advocated to collect non-stimulated saliva obtained by passive 
drooling. 44-46 We suspect that some of the large intra-individual fluctuations in flow rate noted in 
this study may represent a lack of participant compliance, resulting in the collection of 
stimulated saliva. The challenges of controlling the flow rate aspect has been recognized in the 
literature.35 Cultural inhibition to spitting and participants not wanting to be observed whilst 
spitting or drooling makes the control of passive drooling for the collection of non-stimulated 
saliva difficult.36 In this scenario, it may be reasonable to contribute some of the observed 
fluctuations in salivary S-IgA concentration and secretion rates to alterations in saliva flow rate 
caused by individual stimulation of saliva flow. This underlines the importance of 
methodological standardization and possibly supervision during the saliva sampling phase in 
future studies.   
 
Besides these concerns, the observed immediate post-treatment increases in salivary S-IgA 
concentration and S-IgA secretion rates indicate that lymphatic pump treatment may exert some 
influence on the salivary IgA system. The clinical importance of this finding remains 
speculative. At present there is no recognized minimal clinical important difference (MCID) for 
salivary S-IgA. However, decreased levels of salivary S-IgA increase the susceptibility for upper 
respiratory tract infections (URTI). Gleeson37 reported that elite swimmers could expect one 
additional URTI (above their average) when salivary S-IgA levels fell by 6% while Vernon38 
noted that for yacht racing athletes a salivary S-IgA level lower than 40% of their mean healthy 
S-IgA concentration resulted in a 50% chance of contracting an URTI within 3 weeks.  
In order to understand the biological consequences of a short term evoked increase in salivary S-
IgA as observed in this study, long term observational studies including high risk individuals 
have to be initiated.20 
 
To our knowledge this pilot study is the first investigation into the effect of lymphatic pump 
technique on salivary S-IgA. We are also not aware of any studies investigating immune markers 
using single systems research design. Immune markers always show some degree of variation 
within and between subjects and are affected by a range of subject specific and environmental 
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factors.25, 27-29, 50-53 Therefore, where possible, placebo controlled randomized cross-over designs 
are preferred in immune related research.20 The observed increase in salivary S-IgA from 
baseline Day 5 to Post treatment 1 in this study is consistent with increases reported in other 
studies following different types of interventions including meditation,39 relaxation techniques27, 
55, 56 and touch based therapies such as massage therapy57, 58 and reiki.40 However, it is difficult 
to compare salivary S-IgA studies and raises doubt as to whether the increases are supportive of 
any change elicited by these interventions. Many of these studies assess the concentration of 
salivary S-IgA without controlling for the flow rate and therefore neglecting the effect of the 
intervention on the saliva flow rate.41 The lack of assay standardization further complicates 
comparison of salivary S-IgA studies.42 
In this study, by calculating salivary flow rates, we show that observed increases in S-IgA may 
be due to changes in flow rate. We were also able to demonstrate that independent of changes in 
flow rate, in some participants, not only an increase in S-IgA concentration occurred but also an 
enhanced secretion rate.  
 
The results of our study should be interpreted with caution. The baseline values for salivary S-
IgA showed great variability and, for the majority of the participants, the post-treatment increase 
was only transient. It is possible that these observations are a reflection of the individual 
biological sensitivity of the salivary S-IgA responses20 and mirror the inherent difficulty to 
control the determinants of variability in immune markers.43 Related studies are not indicative of 
commonly observed post intervention transience for the salivary S-IgA response since there is a 
general lack of studies implementing further post-intervention measurements (eg.1 hour post-
intervention). However, one unpublished open randomized controlled study by Norton, Saggio & 
Gilliar44 (abstract only available) measured increased salivary S-IgA one hour after a 20 minute 
osteopathic manipulative treatment. For this study no detailed information regarding procedures 
and methods is available.  
While the clinical significance of a transitory increase in salivary S-IgA is currently unknown, 
future, carefully controlled, studies involving multiple, staggered post intervention samples 
would add understanding to the decay aspect of the salivary S-IgA response.  
We must also emphasize that, while the baseline design of this study allowed us to observe the 
day to day variations of individual salivary S-IgA it does not give information on salivary S-IgA 
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changes that occur over hours or minutes. Therefore the observed changes in salivary S-IgA 
immediately post-treatment could easily be interpreted as part of normal variation. However, the 
short timeframe between Baseline 5 and First Post-Treatment measurement in conjunction with 
the substantial changes observed in several participants makes it reasonable to suggest that there 
may be some influence of LPT on salivary S-IgA. Further study is required. 
 
Possible Mechanisms of the salivary S-IgA increase following LPT  
 
The precise mechanisms underlying a LPT- induced increase in salivary S-IgA are speculative. A 
suction effect of LPT on lymphatic nodes, as suggested by Hodge9 may extend to the salivary 
glands resulting in altered fluid flow. Yet, it is unclear to what extent increased fluid movement 
may influence the complex mechanisms involved in endocytosis and transcytosis of S-IgA across 
the epithelium of salivary glands. A suction mediated elevation of salivary S-IgA would account 
for the transience of the S-IgA post-treatment increases observed in this study as the cessation of 
suction can be expected to result in decreased translocation of S-IgA into saliva.  
LPT activated neuroendocrine stimulation may be an explanation for salivary S-IgA elevations 
and fluctuations that were observed in the post treatment measurements of several participants. 
Salivary glands are controlled by the sympathetic and the parasympathetic nervous system. 
These two branches of the autonomic nervous system (ANS) are regulated, amongst other 
factors, by individual responses to perceived stress or relaxation.45, 46 
In this study, the relaxing procedure of the LPT treatment, also bearing in mind the close 
proximity of the vagus nerve to the treated area could reasonably be expected to have elicited a 
parasympathetic response.47 Parasympathetic nervous system (PSNS) influence not only 
generally enhances immune function but also increases mucus production45 possibly providing a 
mechanism that enhances the translocation of IgA based on the the mucophilic properties of its 
secretory component (SC).43 Anyhow, it is just as plausible that individual participants perceived 
LPT, and its associated procedures such as the textbook reading between measurements, as a 
stressful event. In this case, depending on the individually present level of chronic stress, 
perceived acute stress and norepinephrine modulation, either an up or down regulation of 
mucosal immunity takes place.4846 
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To what extent LPT exerts influences on cellular immunity mechanisms of S-IgA synthesis, such 
as plasma cell activation and immunoglobulin isotype switching is pure conjecture. LPT has 
shown to mobilize inflammatory mediators, including interleukins IL and IL 6, into the 
lymphatic ducts of dogs.10 IL promotes the differentiation of B cells into antibody producing 
plasma cells while IL 6 increases antibody production by plasma cells.13, 49 However, these 
immune functions are usually preceded by antigenic stimulation of B-cells which is unlikely to 
occur in a study on healthy subjects and research results from animal studies have to be 
interpreted with caution and their findings cannot always be transferred to humans.50 It could 
also be speculated that the bi-directional nature of the immunesystem40, 48 leads to mechanisms 
that interpret an increased lymph low, following LPT, as an immunological emergency situation 
that requires the mobilization of cellular immune components.  
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Limitations of the study 
 
The extent to which a causal relationship exists between the observed increases in salivary S-IgA 
and the lymphatic pump treatment cannot be determined. To infer causality in a single systems 
research design a stable, flat baseline must be present, showing no trend of improvement and 
changes occurring only after the intervention is applied.2619 The fluctuating baselines in this 
study, though typical for salivary S-IgA,27 therefore do not allow to conclude a causal 
relationship between outcomes and intervention and highlight the need for a controlled group 
design.  
Although the immediate post-treatment change in some participants appears convincing, there 
are, however, alternative explanations challenging the inference that the intervention caused the 
changes in outcomes in this study. The synthesis and the release of immunoglobulin and the 
saliva flow rate underlie autonomic nervous system control and are therefore affected by 
stimulation of the sympathetic and parasympathetic nervous system51 including factors such as 
relaxation, stress, and fear.52 To what extent the individual changes in participants are related to 
the LPT or to other factors, such as lying in a quiet room and being touched, cannot be 
determined. However, it is interesting that significant findings resulted over such a short period 
of time. 
Another threat to the internal validity of this study may have unknowingly been introduced by 
the authors by providing text book reading in between the two post-treatment saliva 
measurements. It could be speculated that this attempt to create similar post- treatment 
conditions for all participants actually elicited an individual stress reaction with subsequent 
variations in salivary S-IgA responses.46, 53 
This study has not attempted to standardize the pressure of the pumping action during the 
lymphatic pump treatment and the reliability of the intervention implementation may be 
questioned.54 
 
The modified single systems research design of this study was chosen for two reasons: one, 
pragmatic considerations based on financial restriction and two, the emerging nature of the topic 
with no previous studies made it reasonable to investigate individual responses first. Single 
systems research studies are noted for their innate problems with external validity and one of the 
most important limitations of this type of design, besides small samples and absence of controls, 
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is the lack of generalizability.19, 54 Although we have demonstrated that LPT may influence 
salivary S-IgA responses in healthy, male subjects of a certain age group the results may not be 
generalizable to other population groups, e. g. adults with disease, the elderly or children. 
There are further considerations related to the single systems research design (SSRD) in this 
study.  
To increase the credibility of SSRD a multiple or non-concurrent baseline approach is 
recommended as it minimizes the possible influence of extraneous variables. We refrained from 
staggering baseline and intervention.  Conducting baselines non-concurrently increases the risk 
that the intervention protocol evolves, compromising direct replication of the treatment.55 
Additionally, bearing in mind the sensitivity of salivary S-IgA levels to external factors such as 
daylight and weather, it seemed more appropriate to attempt to create similar conditions for each 
participant by refraining from implementing staggered baselines.  
Due to the limited number of data points in this study it is not appropriate to apply statistical tests 
for single-subject data such as Trend-Lines or 2 Standard Deviation Band19 and our single 
systems analysis was restricted to visual inspection of data. There is controversy as to the most 
appropriate method of analysis,56 however, the agreement between results of statistical tests and 
visual analysis in single systems research is considered to be high.57 
While the small number of subjects in our study would clearly invalidate parametric statistics19 
we believe that the preliminary nature of this project justifies the statistical group analysis and 
we urge the reader to interpret the statistical significant group result and the effect sizes only in 
regards to their ability in lending strength to the individual results. 
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Suggestions for further research 
 
As the effect sizes in this study were large between baseline and mean of the two post-treatment 
measurements further research of this topic seems justified. To avoid the limitations of the 
present single systems design we would advise a randomized controlled trial. 
The future study design should include a larger number of participants and preferably a control 
group receiving a masked and blinded sham treatment. Ideally subjects are maintained under 
controlled laboratory conditions while treated twice daily and post treatment saliva samples 
being collected in 10 to 15 minute intervals to investigate the decay of the salivary S-IgA 
response.  
To estimate the sample size required based on effect sizes observed in our single systems study 
we would assume an effect size of at least 1.8, bearing in mind that we observed a large effect 
size over a short period of time. Using G*power online analysis based on an alpha error 
probability of 0.05, to achieve a power (1-β error probability) equal to 0.8 and assuming an effect 
size of not less than 0.8 a number of 26 subjects per group would be required. 
However, a more useful way of evaluating the effect of lymphatic pump treatment on salivary S-
IgA levels is to evaluate any change in a degree that is clinically meaningful. Therefore future 
studies should include participants that are adversely affected by low levels of salivary S-IgA 
such as athletes suffering from recurrent upper respiratory tract infections, symptomatic IgA 
deficient individuals and frequently ill children. 
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CONCLUSION 
 
The application of a 7 minute osteopathic lymphatic pump technique appears to increase the 
salivary S-IgA output in healthy male individuals. Increased salivary S-IgA is thought to be 
related to enhanced mucosal immune function and decreased salivary S-IgA is understood to be a 
main factor in the susceptibility of acquiring upper respiratory tract infections. However, the 
possible biological and clinical significance of the findings of this study is presently unclear. 
Whilst the results of this study have to be evaluated bearing in mind the limitations of the single 
systems design we propose that our findings justify further controlled, group investigations. 
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“The effect of the osteopathic lymphatic pump technique on one output of the 
human immune system as measured by salivary Immunoglobulin A”  
 
About this research 
 
You are invited to take part in a study undertaken within the Master of Osteopathy Degree at Unitec NZ.  This 
research investigates the effect of a widely used osteopathic technique on antibody levels in human saliva. Healthy 
males are needed between the ages of 18 and 40 years. 
 
Participants in this project will be asked to: 
 
• Attend a brief appointment to: 
 
o Ensure that the inclusion and exclusion criteria are met, and that they are eligible for the 
project.  
 
o Sign a consent form. 
 
o Answer several questions and fill out a questionnaire about any previous illnesses or diseases. 
 
 
• Attend five times a 15-20 minute appointment on 5 consecutive days to answer a questionnaire about 
lifestyle factors such as sleep, exercise, diet and stress levels and to provide a saliva sample on each of 
these days. You are required to abstain from exercise, food or drink (except for water) 1 hour prior to each 
appointment. 
 
• On the fifth day the above procedure is followed by a 7 minute lymphatic pump treatment that consists of 
rhythmic pumping on the upper chest area. The technique is applied by a qualified osteopath. Immediately 
post treatment and 15 minutes post treatment saliva samples are collected and you are asked to sit quietly 
in between sample taking. 
 
• Saliva samples are collected in labelled, sterile 2ml vials via passive “drooling” through a plastic straw for 5 
minutes or until a certain amount of saliva is collected. The saliva collection vial is held by the participant 
until the required amount is obtained. The vial is then securely sealed by the researcher and transferred to 
the deep freeze storage where it will be held until laboratory analysis commences. 
 
• Consent to the research team’s use of the research data in preparing both a research project dissertation 
and an article for publication. 
 
The researchers 
  
The primary researcher is Heike Ehrlenbach 
This project is being supervised by Dr Craig Hilton and Dr. Andy Stewart. 
 
Participation and consent 
 
You have the right not to participate, or to withdraw from this research project at any time prior to 
commencement of data analysis. This can be done by emailing us, phoning us, or telling us when we contact 
you that you do not want to participate. You also have the right to access your own records on request.   
 
 
Any data collected will be kept in an anomysed format to allow for future re-analysis. This data may be re-
analysed in future student studies. Appropriate research and ethic approval will be sought prior to the use of data 
collected in this study being made available in additional studies.  
 
Participant Information Sheet 
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If you’re interested in participating please complete a consent form(attached)for this project and return it to Heike 
Ehrlenbach 
 
 
Getting help 
 
Please contact any one of us should you have any queries or require any help with this research project. 
 
Heike Ehrlenbach: heike@raglan.co.nz 
 
Craig Hilton:           chilton@unitec.ac.nz 
 
Andy Stewart: astewart@unitec.ac.nz 
  09 815 4321 x 8384 
 
 
Information and concerns 
If you would like further information about the project you can call or email the above addresses. If at any time you 
are confused or concerned about the research project, you can contact Heike Ehrlenbach, the primary researcher, on 
the details above. 
 
If you have any concerns about the way in which the research is being conducted, you can contact the following: 
Health Advocates: Advocates Network Services Trust, Phone (09) 6235799, (0800)205555, Fax (09)6235798, PO 
Box 9983, Newmarket, Auckland. 
 
Confidentiality 
 
Your confidentiality and anonymity will be protected in the following ways: 
 
• Information and data collected from you during this research will be labelled with an identification number for 
the purpose of anonymously comparing your data. 
 
• All computer records will be accessible solely by passwords held only by the researchers. 
 
• Any data derived from the research will be anonymous and your identity will be kept confidential. 
 
 
A copy of the final report will be available at the Unitec NZ library, and a plain English summary will be available to 
participants and other interested parties. Summaries and recommendations may be published in research journals. 
 
Finally, we would like to extend our appreciation and thanks to you for your valuable contribution to this research. 
 
UREC REGISTRATION NUMBER: 2009-974 
This study has been approved by the UNITEC Research Ethics Committee from 24-06-2009 to 24-06-
2010.  If you have any complaints or reservations about the ethical conduct of this research, you 
may contact the Committee through the UREC Secretary (ph: 09 815-4321 ext 7248).  Any issues you 
raise will be treated in confidence and investigated fully, and you will be informed of the outcome. 
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PARTICIPANT CONSENT FORM  
 
 
The effect of the osteopathic lymphatic pump technique on one output of the 
human immune system as measured by salivary Immunoglobulin A 
 
This research project investigates the effect of an osteopathic technique on salivary antibody A levels. The research 
is undertaken by Heike Ehrlenbach, a Master of Osteopathy student at Unitec, New Zealand and will be supervised 
by Dr. Craig Hilton and Dr. Andrew Stewart. 
 
Name of Participant:_________________________ 
 
I have seen the Participant Information Sheet for the project titled ‘The effect of the osteopathic lymphatic pump 
technique on one output of the human immune system as measured by salivary immunoglobulin A’.I have had the 
opportunity to read the contents of the information sheet and to discuss the project with Heike Ehrlenbach, and I am 
satisfied with the explanations I have been given.  I understand that the anonymised data from her project will be held 
indefinitely for the purposes of future analysis and research.  I understand that taking part in this project is voluntary 
(my choice) and that I may withdraw from the project at any time up until one week after the last data collection and 
this will in no way affect my access to the services provided by Unitec NZ, or the Unitec Osteopathic Clinic. 
I understand that I can withdraw from the study if, for any reason, I want to do so. 
 
I understand that I can withdraw from the study at anytime up until one week after the last data collection.I 
understand that my participation in this project is confidential, and no material that could identify me will be used in 
any reports of this project.   
 
I acknowledge that any materials collected during the study will be stored securely so that only the researchers may 
access them. I understand that my data collection records will be made available on request. I understand that any 
material collected will made anonymous and kept indefinitely to enable future re-analysis. 
I have had enough time to consider whether I want to take part. 
I know whom to contact if I have any questions or concerns about the project. 
 
The principal researcher for this project is Heike Ehrlenbach.   
Contact details: heike@raglan.co.nz 
 
 
Signature: _____________________________ (participant)     Date:________________ 
 
 
Project explained by Heike Ehrlenbach 
 
Signature:_____________________________            Date:________________ 
 
The participant should retain a copy of this consent form. 
UREC REGISTRATION NUMBER: 2009-974 
This study has been approved by the UNITEC Research Ethics Committee from 24-06-2009 to 24-06-2010.  If 
you have any complaints or reservations about the ethical conduct of this research, you may contact the 
Committee through the UREC Secretary (ph: 09 815-4321 ext 7248).  Any issues you raise will be treated in 
confidence and investigated fully, and you will be informed of the outcome. 
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Study Enrolment Questionnaire 
Name:     
Address :                            
Date of birth:                                              
Phone number:                                                                   Email:                             
Male Female Smoker:  yes     no 
Ethnicity:                                 Weight:    Height: 
 
1. Please list below any medications that you are presently taking  
2. Do you have any allergies?  yes     no 
3. Do you presently suffer from any viral or bacterial infection?  yes     no 
4. Do you presently have any mouth ulcers, tooth or gum infections?  yes     no 
5. Did you recently have any dental extractions or dental surgery?  yes     no 
6. Have you ever been diagnosed with any infectious disease such as AIDS, Hepatitis or Syphilis?  yes   
 no  
7. Is there a history of haemophilia in your family?   yes      no 
8. Have you ever been diagnosed with IgA deficiency?  yes      no 
9. Have you ever been diagnosed with an autoimmune disorder?  yes      no 
10. Have you ever been diagnosed with any form of cancer, sickle cell disease, aneurysms, cardiac failure 
or varicose veins?  yes     no 
11. Did you recently (within last 2 weeks) return from a long distance flight?  yes     no 
12. Do you ever experience pain in your legs during exercising? yes     no 
13. Have you ever been diagnosed with deep vein thrombosis? yes     no 
14. Did you recently undergo any procedure or surgery in the upper body area?  yes     no 
15. Do you suffer from any condition/illness for which you are currently receiving treatment?   
 yes     no 
The following questions aim to establish lifestyle factors that are known to have an 
influence on salivary antibodies. Please answer as indicated. 
Listed below are a series of statements about people’s exercise habits. Please circle the number 
that reflects how often you could make the following statements:  
1 – NEVER 2 – SOMETIMES 3 – USUALLY 4 – ALWAYS  
1.      I engage in physical exercise on a daily basis.                  1    2     3    4  
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2.      I engage in one/more of the following forms of exercise: walking,     
jogging/running or weightlifting.           1    2     3    4  
3.      I exercise more than three days per week.    1    2     3    4  
4. How often do you take part in vigorous exercise (sufficient to make you slightly       breathless and 
makes your heart beat faster) which lasts for 20 minutes or more? (Please circle) 
A     occasionally or never 
B     once or twice a week 
C     three times a week or more 
 
 
 
 
Listed below are some questions regarding your diet. Please answer as indicated. 
 
1. Are you currently dieting to reduce your weight? yes     no 
 
2. Do you regularly take any dietary supplements?          yes     no 
    If yes, please list them here:   
3. How many standard units of alcohol do you drink per week?  
 
Signature:                                                                Date: 
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Daily Pre-Sample Questionnaire 
 
 
 
 
 
 
 
Pre- Sample Collection  Questionnaire 
 
 
Date:_______________________     Name:_________________________________ 
 
 
This questionnaire aims to determine factors that may have influenced your salivary 
antibody levels in the past 24 hours. Please answer the following questions as indicated. 
 
 
1. Did you engage in any exercise in the last 24 hours (sufficient to make you slightly   
breathless and make your heart beat faster for more than 20 minutes?   Yes    No     
   If you answered yes, please indicate time:_________________________________________ 
 
 
2. Did you drink any alcohol or coffee in the last 24 hours?                     Yes    No     
    If you answered yes, please indicate amount and time _______________________________ 
 
 
3. Did you have any food, drink (other than water) in the last hour?      Yes    No     
    If you answered yes, please indicate type and amount:_______________________________ 
 
 
 4. How many hours do you usually sleep per night?__________________________________ 
 
 
 5. How many hours did you sleep last night?________________________________________ 
   
 
 6. How would you rate your average stress level in the last 24 hours on a scale from 0 to 10?  
 
      1    2     3    4     5     6      7     8     9    10   (please circle) 
 
 
 7. How would you rate your stress level at this moment on a scale from 0 to 10?  
 
      1    2     3    4     5     6      7     8     9    10   (please circle) 
 
  8. Did you have any symptoms of a bacterial or viral infection in the past 24 hours?  
      (Temperature, sore throat, cough, runny nose) 
      Yes    No     
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Daily Baseline Collection Day 1- 4 
 
Participant Number: Weight :          Height: 
 
Base line Day 1        Date:                  Time:                                                                     
Collection vial number for baseline sample A  
Collection time for baseline sample A  
Weight of baseline sample A (vial with saliva)  
  
Collection vial number for baseline sample B  
Collection time for baseline sample B  
Weight of baseline sample B  
 
Base line Day 2        Date:                 Time: 
Collection vial number for baseline sample A  
Collection time for baseline sample A  
Weight of baseline sample A (vial with saliva)  
  
Collection vial number for baseline sample B  
Collection time for baseline sample B  
Weight of baseline sample B  
 
Baseline Day 3       Date:                    Time: 
Collection vial number for baseline sample A  
Collection time for baseline sample A  
Weight of baseline sample A (vial with saliva)  
  
Collection vial number for baseline sample B  
Collection time for baseline sample B  
Weight of baseline sample B  
 
Baseline Day 4         Date:                     Time: 
Collection vial number for baseline sample A  
Collection time for baseline sample A  
Weight of baseline sample A (vial with saliva)  
  
Collection vial number for baseline sample B  
Collection time for baseline sample B  
Weight of baseline sample B  
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Data Collection Day 5  Pre- and Post-intervention sample data 
 
 
 
Participant number: 
Date: 
Time: 
 
 
 Time in minutes 
and seconds 
Collection vial 
number 
Collection vial  
Weight ( after 
saliva collection) 
Collection time of 1st 
pre-treatment 
SampleA  
   
Collection time of 1st 
pre-treatment 
SampleB  
   
Start time of  
treatment Session  
 
Finish time of 
Treatment  Session  
 
Collection time of 1st 
post-treatment 
SampleA  
   
Collection time of 1st 
post-treatment 
SampleB 
   
Start time of 2nd Post-
Treatment sample 
(10min. post 
treatment) 
 
Collection time of 2nd 
post-treatment 
SampleA  
   
Collection time of 2nd 
post-treatment 
SampleB  
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Saliva Sample Vial Codes 
 
 
B = baseline samples a and b(each day the baseline sample is done in duplicate ) 
B5a +B5b = last baseline sample also acts asthe pre-treatment sample (done in duplicate) 
P1a +P1b = 1st post-treatment sample, immediately after treatment (done in duplicate) 
P2a+P2b = 2nd post-treatment sample, 10 minutes post treatment (done in duplicate) 
 
 
 
 
Part. 
Nr. 
B1a B1b B2a B2b B3a B3b B4a B4b B5a B5b P1a P1b P2a P2b 
1 1 2 3 4 5 6 7 8 9 10 11 12 13 14 
2 15 16 17 18 19 20 21 22 23 24 25 26 27 28 
3 29 30 31 32 33 34 35 36 37 38 39 40 41 42 
4 43 44 45 46 47 48 49 50 51 52 53 54 55 56 
5 57 58 59 60 61 62 63 64 65 66 67 68 69 70 
6 71 72 73 74 75 76 77 78 79 80 81 82 83 84 
7 85 86 87 88 89 90 91 92 93 94 95 96 97 98 
8 99 100 101 102 103 104 105 106 107 108 109 110 111 112 
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Immune related Osteopathic Techniques 
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Lymphatic Pump Techniques 
 
All lymphatic pump techniques (LPT) aim to influence pressure gradients between thoracic and 
abdominal cavity to improve lymphatic fluid flow and to aid tissue decongestion (Hruby & 
Hoffman, 2007; Ward, 2003). The clinically most commonly used LPT’s are described below. 
 
Thoracic pump 
 
Patient supine, practitioner standing at head of table. Practitioner places hands on patient’s 
thorax with thenar eminences over pectoralis muscle and fingers spread out facing towards the 
feet and slightly lateral (Figure 1). A rhythmic pumping action is created by the practitioner by 
alternating pressure and release. The pumping rate can range from 60-120 times per minute 
depending on individual tissue response. The patient is asked to continue to breathe normally 
(Ward, 2003). 
 
 
Figure D5 Thoracic pump  (Ward, 2003) 
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Abdominal pump 
 
Patient supine, practitioner stands at side of table. Practitioner’s palms are placed on the patient’s 
abdomen with the fingers pointing to the patients head (Figure 2). With extended arms and 
locked elbows a pumping motion is created at a rate of 20-30 times/minute (Ward, 2003). 
 
Figure D6 Abdominal pump (Ward, 2003) 
 
Pedal pump 
Patient supine, practitioner standing at patients feet  
Practitioner grasps patient’s feet and introduces a rhythmical alternating hyper dorsiflexion to the 
patient’s feet creating an oscillating pump movement through the longitudinal axis of the 
patient’s body (Figure 3)(Ward, 2003). 
 
Figure D7  Pedal pump (Ward, 2003) 
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Liver pump (liver quiver) 
 
Patient supine, practitioner on right side of patient facing the patient. 
Practitioner’s left hand is placed under patient’s lower ribcage while right hand is lies on the 
abdominal wall below the costal margin (Figure 4). The patient is asked to inhale and exhale 
deeply and on each exhalation the practitioner employs a vibratory movement of the right hand 
on the liver (Ward, 2003). 
 
Figure D8 Liver pump (liver quiver)(Ward, 2003) 
 
Spleenic pump 
 
Patient lying on their right side, practitioner standing behind patient with patients left arm draped 
over practitioners shoulder. Practitioner hands are placed anterior and posterior on lower thorax 
(Figure 5).On each patient exhalation the practitioner introduces a vibratory movement through 
the rib cage. This technique can also be applied over the liver area with the patient lying on their 
left side (Ward, 2003). 
 
Figure D9 Spleenic pump,( technique here shown on liver)(Ward, 2003) 
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Other Osteopathic Techniques and their effect on the Immune system. 
Rib raising techniques augment sympathetic nervous system (SNS) activity to lymphatic vessels. 
A similar effect is achieved by inhibiting paraspinal tissues of the trunk. Both techniques 
stimulate the thoracic sympathetic chain ganglia which are situated near the rib heads. Initial 
increase in SNS outflow is followed by decreased sympathetic activity resulting in improved 
lymph flow and drainage of the tissues that receive their sympathetic supply from the treated 
spinal area (Guyton & Hall, 2000; Kuchera & Kuchera, 1993; Ward, 2003). 
Fascia release treatment normalizes tension throughout the connective tissues that form sheets 
and diaphragms within the body. Lymphatic vessels are closely associated with and have to pass 
through fascia. The thoracic inlet (a diaphragm formed by fascia in the area of the upper thoracic 
vertebrae, the first two ribs and the manubrium of the sternum) is of specific importance to 
lymph flow since both lymphatic ducts have to pass through this area (Paoletti, 2006; Thieme, 
2006; Ward, 2003).  
Doming of the abdominal diaphragm is a technique that aims to optimize the function of the 
diaphragm muscle. Efficient contraction and relaxation of the abdominal diaphragm produces 
pressure gradients between the thoracic and abdominal body cavity. These pressure gradients 
function as intrinsic pumps supporting the lymphatic circulation. Doming techniques are also 
applied to the pelvic diaphragm, a muscle sling in the pelvis that provides support for the pelvic 
organs. Restriction in the pelvic diaphragm can affect fluid flow in lymphatic channels and cause 
congestion in the lower extremities and the pelvic organs (Kuchera & Kuchera, 1993; Stone, 
1999; Ward, 2003).  
Petrissage(kneading or squeezing) and Effleurage(stroking) of the extremities, in a distal to 
proximal (towards the heart) direction, facilitates lymph flow from the appendages to the thorax 
and to the abdomen. These techniques, in combination with gentle traction, are also employed 
around the mandible, the cervical and pectoral muscles and on the abdomen, with the aim to 
enhance tissue drainage. 
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Raw Data and Transformation Calculations 
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Plate read Plate 1 full plate  
 
 
P late: full plate    Date C reated: 14/07/2010 5:27:32 p.m.
 
R aw Data
0.177 0.178 0.582 0.583 0.846 0.909 0.695 0.765 0.738 0.787 0.477 0.506
0.284 0.287 0.243 0.256 0.906 0.912 0.706 0.721 0.581 0.623 0.53 0.555
0.424 0.407 0.705 0.723 0.841 0.862 0.662 0.64 0.633 0.641 0.18 0.607
0.587 0.583 0.673 0.675 0.758 0.758 0.69 0.672 0.506 0.53 0.283 0.269
0.77 0.779 0.586 0.582 0.808 0.802 0.629 0.617 0.554 0.554 0.448 0.051
0.84 0.837 0.638 0.65 0.73 0.731 0.667 0.654 0.539 0.57 0.606 0.909
0.894 0.929 0.746 0.788 0.714 0.726 0.681 0.651 0.561 0.601 0.751 0.702
0.049 0.048 0.819 0.908 0.764 0.742 0.703 0.729 0.523 0.539 0.92 0.501
 
T emplate
S T D01 S T D01 C T L 1 C T L 1 S MP 61 S MP 61 S MP 77 S MP 77 S MP 93 S MP 93 S MP 109 S MP 109
S T D02 S T D02 C T L 2 C T L 2 S MP 63 S MP 63 S MP 79 S MP 79 S MP 95 S MP 95 S MP 111 S MP 111
S T D03 S T D03 S MP 49 S MP 49 S MP 65 S MP 65 S MP 81 S MP 81 S MP 97 S MP 97 S T D01 C T L 1
S T D04 S T D04 S MP 51 S MP 51 S MP 67 S MP 67 S MP 83 S MP 83 S MP 99 S MP 99 S T D02 C T L 2
S T D05 S T D05 S MP 53 S MP 53 S MP 69 S MP 69 S MP 85 S MP 85 S MP 101 S MP 101 S T D03 B L K
S T D06 S T D06 S MP 55 S MP 55 S MP 71 S MP 71 S MP 87 S MP 87 S MP 103 S MP 103 S T D04 C T L 3
C T L 3 C T L 3 S MP 57 S MP 57 S MP 73 S MP 73 S MP 89 S MP 89 S MP 105 S MP 105 S T D05 S MP 23
B L K B L K S MP 59 S MP 59 S MP 75 S MP 75 S MP 91 S MP 91 S MP 107 S MP 107 S T D06 S MP 25
 
T ransformation R esults
0.14822 0.149381 0.532667 0.533667 0.796667 0.859667 0.645667 0.715667 0.688667 0.737667 0.427667 0.456667
0.272446 0.275929 0.224845 0.239938 0.994582 1.001548 0.762384 0.779799 0.61726 0.666022 0.55805 0.587074
0.434985 0.415248 0.761223 0.782121 0.919118 0.943498 0.7113 0.685759 0.677632 0.68692 0.151703 0.647446
0.624226 0.619582 0.724071 0.726393 0.822755 0.822755 0.743808 0.72291 0.530186 0.55805 0.271285 0.255031
0.836687 0.847136 0.623065 0.618421 0.880805 0.873839 0.672988 0.659056 0.585913 0.585913 0.462848 0.001667
0.917957 0.914474 0.683437 0.697368 0.790248 0.791409 0.717105 0.702012 0.568498 0.604489 0.646285 0.859667
0.844667 0.879667 0.808824 0.857585 0.771672 0.785604 0.733359 0.698529 0.59404 0.64048 0.814628 0.75774
-0.00033 -0.00133 0.893576 0.996904 0.829721 0.80418 0.758901 0.789087 0.549923 0.568498 1.010836 0.524381
 
C oncentrations / Dilutions
600 600 1 1 5 5 5 5 5 5 5 5
200 200 1 1 5 5 5 5 5 5 5 5
66.7 66.7 5 5 5 5 5 5 5 5 600 1
22.2 22.2 5 5 5 5 5 5 5 5 200 1
7.4 7.4 5 5 5 5 5 5 5 5 66.7
2.5 2.5 5 5 5 5 5 5 5 5 22.2 1
1 1 5 5 5 5 5 5 5 5 7.4 5
5 5 5 5 5 5 5 5 2.5 5
 
C alculated C oncentrations
636.5913 627.1493 39.46139 39.24882 43.91919 28.27375 107.0671 72.17242 84.25599 63.40903 352.9314 299.365
192.6892 187.703 283.8902 249.4187 7.475019 6.772568 54.58596 48.95436 125.0264 95.67189 172.0759 147.1849
67.68703 75.84736 54.97794 48.23748 17.28235 13.6515 74.02274 85.6531 89.66281 85.093 608.8914 21.20497
24.0764 24.692 68.71677 67.78601 36.87309 36.87309 61.12047 69.18599 199.9699 172.0759 194.3914 220.5503
6.689881 6.205134 121.1447 124.2409 23.99162 25.35453 92.02585 99.444 148.1086 148.1086 57.83778 ??????
3.493423 3.605619 86.78273 80.19023 45.78871 45.44641 71.57113 78.08873 162.6666 133.9816 21.34079 5.65475
6.317542 4.842234 40.52861 28.71954 51.52551 47.17662 65.05409 79.66048 141.7595 110.1586 7.795279 56.16673
?????? ?????? 21.61084 7.237279 35.13314 41.80112 55.76831 46.13287 179.7727 162.6666 1.17717 206.3488
 
B lanked Data
0.127667 0.128667 0.532667 0.533667 0.796667 0.859667 0.645667 0.715667 0.688667 0.737667 0.427667 0.456667
0.234667 0.237667 0.193667 0.206667 0.856667 0.862667 0.656667 0.671667 0.531667 0.573667 0.480667 0.505667
0.374667 0.357667 0.655667 0.673667 0.791667 0.812667 0.612667 0.590667 0.583667 0.591667 0.130667 0.557667
0.537667 0.533667 0.623667 0.625667 0.708667 0.708667 0.640667 0.622667 0.456667 0.480667 0.233667 0.219667
0.720667 0.729667 0.536667 0.532667 0.758667 0.752667 0.579667 0.567667 0.504667 0.504667 0.398667 0.001667
0.790667 0.787667 0.588667 0.600667 0.680667 0.681667 0.617667 0.604667 0.489667 0.520667 0.556667 0.859667
0.844667 0.879667 0.696667 0.738667 0.664667 0.676667 0.631667 0.601667 0.511667 0.551667 0.701667 0.652667
-0.00033 -0.00133 0.769667 0.858667 0.714667 0.692667 0.653667 0.679667 0.473667 0.489667 0.870667 0.451667
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Plate Read Plate 2 Half Plate 
 
 
P late: 1/2 plate    Date C reated: 14/07/2010 5:29:17 p.m.
 
R aw Data
0.506 0.514 0.669 0.603 0.724 0.725
0.568 0.571 0.605 0.615 0.628 0.653
0.577 0.591 0.608 0.613 0.707 0.852
0.61 0.626 0.658 0.668 0.562 0.569
0.515 0.523 0.454 0.469 0.563 0.566
0.426 0.428 0.523 0.541 0.75 0.77
0.46 0.496 0.688 0.724 0.751 0.756
0.646 0.704 0.734 0.75 0.736 0.725
 
T emplate
S MP 01 S MP 01 S MP 17 S MP 17 S MP 33 S MP 33
S MP 03 S MP 03 S MP 19 S MP 19 S MP 35 S MP 35
S MP 05 S MP 05 S MP 21 S MP 21 S MP 37 S MP 37
S MP 07 S MP 07 S MP 23 S MP 23 S MP 39 S MP 39
S MP 09 S MP 09 S MP 25 S MP 25 S MP 41 S MP 41
S MP 11 S MP 11 S MP 27 S MP 27 S MP 43 S MP 43
S MP 13 S MP 13 S MP 29 S MP 29 S MP 45 S MP 45
S MP 15 S MP 15 S MP 31 S MP 31 S MP 47 S MP 47
 
T ransformation R esults
0.530435 0.53971 0.71942 0.642899 0.783188 0.784348
0.602319 0.605797 0.645217 0.656812 0.671884 0.70087
0.612754 0.628986 0.648696 0.654493 0.763478 0.931594
0.651014 0.669565 0.706667 0.718261 0.595362 0.603478
0.54087 0.550145 0.470145 0.487536 0.596522 0.6
0.437681 0.44 0.550145 0.571014 0.813333 0.836522
0.477101 0.518841 0.741449 0.783188 0.814493 0.82029
0.692754 0.76 0.794783 0.813333 0.797101 0.784348
 
C oncentrations / Dilutions
5 5 5 5 5 5
5 5 5 5 5 5
5 5 5 5 5 5
5 5 5 5 5 5
5 5 5 5 5 5
5 5 5 5 5 5
5 5 5 5 5 5
5 5 5 5 5 5
 
C alculated C oncentrations
199.7009 189.9459 70.61207 108.7071 47.91045 47.55716
135.5627 133.0372 107.3317 100.6869 92.59526 78.60157
128.1198 117.3015 105.2982 101.9856 54.21842 15.36573
103.9618 93.80172 76.02875 71.09108 140.7519 134.7158
188.7617 179.5576 277.676 252.2417 139.874 137.2717
333.269 328.8997 179.5576 160.4789 39.31906 33.48879
267.1758 212.6367 61.99166 47.91045 39.01221 37.50273
82.32529 55.39313 44.46212 39.31906 43.79458 47.55716
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Standard Curve  
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Raw Data Conversions  
 
Sample 
number  
Weight 
empty 
vial 
(mg) 
Weight 
full 
vial 
(mg) 
Weight 
of 
saliva 
sample 
(gm) 
Collection 
time of 
sample 
(sec) 
S-IgA 
concentration 
(μg/ml) 
Collection 
time of 
saliva 
sample 
(min) 
Flow rate 
(ml/min) 
S-IgA 
Secretion 
rate 
(μg/min) 
1 1091 1485 0.394 80 194.82 1.33 0.296 57.57 
3 1110 1526 0.416 97 134.30 1.62 0.257 34.56 
5 1153 1633 0.48 70 122.71 1.17 0.411 50.49 
7 1103 1687 0.584 22 98.88 0.37 1.593 157.49 
9 1069 1554 0.485 80 184.16 1.33 0.364 66.99 
11 1155 1778 0.623 63 331.09 1.05 0.593 196.44 
13 1108 1586 0.478 130 239.91 2.17 0.221 52.93 
15 1111 1328 0.217 190 68.86 3.17 0.069 4.72 
17 1167 1542 0.375 9 89.66 0.15 2.500 224.15 
19 1122 1557 0.435 13 104.01 0.22 2.008 208.82 
21 1084 1836 0.752 27 103.64 0.45 1.671 173.20 
23 1137 1691 0.554 15 73.56 0.25 2.216 163.01 
25 1057 1607 0.55 75 264.96 1.25 0.440 116.58 
27 1166 1580 0.414 87 170.02 1.45 0.286 48.54 
29 1165 2099 0.934 64 54.95 1.07 0.876 48.12 
31 1081 1968 0.887 29 41.89 0.48 1.835 76.88 
33 1103 2438 1.335 15 47.73 0.25 5.340 254.88 
35 1050 1871 0.821 26 85.60 0.43 1.895 162.18 
37 1121 2149 1.028 52 34.79 0.87 1.186 41.27 
39 1125 2282 1.157 42 137.73 0.70 1.653 227.65 
41 1026 2043 1.017 18 138.57 0.30 3.390 469.76 
43 1058 2085 1.027 66 36.40 1.10 0.934 33.98 
45 1057 1883 0.826 42 38.26 0.70 1.180 45.14 
47 1059 1944 0.885 23 45.61 0.38 2.309 105.29 
49 1025 1834 0.809 19 51.61 0.32 2.555 131.84 
51 1132 2085 0.953 24 68.25 0.40 2.383 162.61 
53 1058 1964 0.906 22 122.69 0.37 2.471 303.16 
55 1052 2331 1.279 15 83.49 0.25 5.116 427.11 
57 1119 2385 1.266 72 34.62 1.20 1.055 36.53 
59 1159 2271 1.112 30 14.42 0.50 2.224 32.08 
61 1094 2131 1.037 22 36.10 0.37 2.828 102.09 
63 1119 2376 1.257 20 7.12 0.33 3.771 26.86 
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Sample 
number  
Weight 
empty 
vial 
(mg) 
Weight 
full 
vial 
(mg) 
Weight 
of 
saliva 
sample 
(gm) 
Collection 
time of 
sample 
(sec) 
S-IgA 
concentration 
(μg/ml) 
Collection 
time of 
saliva 
sample 
(min) 
Flow rate 
(ml/min) 
S-IgA 
Secretion 
rate 
(μg/min) 
65 1019 2356 1.337 23 15.47 0.38 3.488 53.95 
67 1073 1963 0.89 18 36.87 0.30 2.967 109.39 
69 1143 2301 1.158 20 29.67 0.33 3.474 103.08 
71 1070 2152 1.082 198 45.62 3.30 0.328 14.96 
73 1111 2167 1.056 48 49.35 0.80 1.320 65.14 
75 1072 2211 1.139 55 38.47 0.92 1.243 47.80 
77 1097 2307 1.21 57 89.62 0.95 1.274 114.15 
79 1092 2193 1.101 36 51.77 0.60 1.835 95.00 
81 1091 2244 1.153 28 79.84 0.47 2.471 197.26 
83 1115 2225 1.11 38 65.15 0.63 1.753 114.19 
85 1172 1866 0.694 16 95.74 0.27 2.603 249.15 
87 1153 1301 0.148 29 74.83 0.48 0.306 22.91 
89 1114 1471 0.357 95 72.36 1.58 0.225 16.31 
91 1134 1647 0.513 37 50.95 0.62 0.832 42.38 
93 1131 2027 0.896 30 73.83 0.50 1.792 132.31 
95 1128 2069 0.941 12 110.35 0.20 4.705 519.19 
97 1110 1895 0.785 45 82.88 0.75 1.047 86.75 
99 1085 2076 0.991 93 186.02 1.55 0.639 118.93 
101 1141 2078 0.937 52 148.11 0.87 1.081 160.13 
103 1154 2002 0.848 49 148.32 0.82 1.038 154.01 
105 1070 1956 0.886 45 125.96 0.75 1.181 148.80 
107 1116 1874 0.758 56 171.22 0.93 0.812 139.05 
109 1122 1876 0.754 70 326.15 1.17 0.646 210.78 
111 1106 1794 0.688 34 159.63 0.57 1.214 193.81 
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S-IgA concentration duplicates 
 
 
  Participant Sample 
[IgA] 
1(μg/ml) 
[IgA] 2 
(μg/ml) 
 S-IgA 
concentration 
μg/ml 
Duplicate 
difference 
(μg/ml) 
1 Baseline Day 1 199.70 189.95 194.82 9.76 
 Baseline Day 2 135.56 133.04 134.30 2.53 
 Baseline Day 3 128.12 117.30 122.71 10.82 
 Baseline Day 4 103.96 93.80 98.88 10.16 
 Baseline Day 5 188.76 179.56 184.16 9.20 
 Post ttt 1 minute 333.27 328.90 331.08 4.37 
 
Post ttt 10 
minutes 267.18 212.64 239.91 54.54 
2 Baseline Day 1 82.33 55.39 68.86 26.93 
 Baseline Day 2 70.61 108.71 89.66 38.10 
 Baseline Day 3 107.33 100.69 104.01 6.65 
 Baseline Day 4 105.30 101.99 103.64 3.31 
 Baseline Day 5 76.03 71.09 73.56 4.94 
 Post ttt 1 minute 277.68 252.24 264.96 25.43 
 
Post ttt 10 
minutes 179.56 160.48 170.02 19.08 
3 Baseline Day 1 61.99 47.91 54.95 14.08 
 Baseline Day 2 44.46 39.32 41.89 5.14 
 Baseline Day 3 47.91 47.56 47.73 0.35 
 Baseline Day 4 92.60 78.60 85.60 13.99 
 Baseline Day 5 54.22 15.37 34.79 38.85 
 Post ttt 1 minute 140.75 134.72 137.73 6.04 
 
Post ttt 10 
minutes 139.87 137.27 138.57 2.60 
4 Baseline Day 1 39.32 33.49 36.40 5.83 
 Baseline Day 2 39.01 37.50 38.26 1.51 
 Baseline Day 3 43.80 47.56 45.68 3.76 
 Baseline Day 4 54.98 48.24 51.61 6.74 
 Baseline Day 5 68.72 67.79 68.25 0.93 
 Post ttt 1 minute 121.15 124.24 122.69 3.10 
 
Post ttt 10 
minutes 86.78 80.19 83.49 6.59 
5 Baseline Day 1 40.53 28.72 34.62 11.81 
 Baseline Day 2 21.61 7.24 14.42 14.37 
 Baseline Day 3 43.92 28.27 36.10 15.65 
 Baseline Day 4 7.48 6.77 7.12 0.70 
 Baseline Day 5 17.28 13.65 15.47 3.63 
 Post ttt 1 minute 36.87 36.87 36.87 0.00 
 
Post ttt 10 
minutes 29.99 29.36 29.67 0.64 
99 
 
Participant Sample 
[IgA] 
1(μg/ml) 
[IgA] 2 
(μg/ml) 
 S-IgA 
concentration 
μg/ml 
Duplicate 
difference 
(μg/ml) 
6 Baseline Day 1 45.79 45.45 45.62 0.34 
 Baseline Day 2 51.53 47.18 49.35 4.35 
 Baseline Day 3 35.13 41.80 38.47 6.67 
 Baseline Day 4 107.07 72.17 89.62 34.90 
 Baseline Day 5 54.59 48.95 51.77 5.63 
 Post ttt 1 minute 74.02 85.65 79.84 11.63 
 
Post ttt 10 
minutes 61.12 69.19 65.15 8.07 
7 Baseline Day 1 92.03 99.44 95.74 7.42 
 Baseline Day 2 71.57 78.09 74.83 6.52 
 Baseline Day 3 65.05 79.66 72.36 14.61 
 Baseline Day 4 55.77 46.13 50.95 9.64 
 Baseline Day 5 84.26 63.41 73.83 20.85 
 Post ttt 1 minute 125.03 95.67 110.35 29.35 
 
Post ttt 10 
minutes 80.66 85.09 82.88 4.43 
8 Baseline Day 1 199.97 172.08 186.02 27.89 
 Baseline Day 2 148.11 148.11 148.11 0.00 
 Baseline Day 3 162.67 133.98 148.32 28.69 
 Baseline Day 4 141.76 110.16 125.96 31.60 
 Baseline Day 5 179.77 162.66 171.22 17.11 
 Post ttt 1 minute 352.93 299.37 326.15 53.57 
 
Post ttt 10 
minutes 172.08 147.19 159.63 24.89 
     
Mean         
13.04                        
     
STDV         
13.13 
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Guide for Authors 
 
International Journal of Osteopathic Medicine 
 
An official journal of:  
 
• General Osteopathic Council (UK) 
• Australian Osteopathic Association 
• Ontario Association of Osteopathic Manual Practitioners 
Former title: Journal of Osteopathic Medicine 
 
The journal Editors welcome contributions for publication from the following categories: Letters 
to the Editor, Reviews and Original Articles, Commentaries and Clinical Practice case studies 
with educational value. 
 
Online Submission  
 
Submission to this journal proceeds totally online.( http://ees.elsevier.com/ijom) you will be 
guided stepwise through the creation and uploading of the various files. The system 
automatically converts source files to a single Adobe Acrobat PDF version of the article, which 
is used in the peer-review process. Please note that even though manuscript source files are 
converted to PDF at submission for the review process, these source files are needed for further 
processing after acceptance. All correspondence, including notification of the Editor's decision 
and requests for revision, takes place by e-mail and via the Author's homepage, removing the 
need for a hard-copy paper trail. 
 
The above represents a very brief outline of this form of submission. It can be advantageous to 
print this "Guide for Authors" section from the site for reference in the subsequent stages of 
article preparation. 
 
Submission of an article implies that the work described has not been published previously 
(except in the form of an abstract or as part of a published lecture or academic thesis), that it is 
not under consideration for publication elsewhere, that its publication is approved by all authors 
and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if 
accepted, it will not be published elsewhere in the same form, in English or in any other 
language, without the written consent of the Publisher. 
 
Types of contributions  
Letters to the Editor as is common in biomedical journals the editorial board welcomes critical 
response to any aspect of the journal. In particular, letters that point out deficiencies and that add 
to, or further clarify points made in a recently published work, are welcomed. The Editorial 
Board reserves the right to offer authors of papers the right of rebuttal, which may be published 
alongside the letter. 
 
Reviews and Original Articles These should be either i) reports of new findings related to 
osteopathic medicine that are supported by research evidence. These should be original, 
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previously unpublished works. The report will normally be divided into the following sections: 
abstract, introduction, materials and methods, results, discussion, conclusion, references. Or ii) 
critical or systematic review that seeks to summarize or draw conclusions from the established 
literature on a topic relevant to osteopathic medicine. 
 
Short review The drawing together of present knowledge in a subject area, in order to provide a 
background for the reader not currently versed in the literature of a particular topic. Shorter in 
length than and not intended to be as comprehensive as that of the literature review paper. With 
more emphasis on outlining areas of deficit in the current literature that warrant further 
investigation. 
 
Research Note Findings of interest arising from a larger study but not the primary aim of the 
research endeavor, for example short experiments aimed at establishing the reliability of new 
equipment used in the primary experiment or other incidental findings of interest, arising from, 
but not the topic of the primary research. Including further clarification of an experimental 
protocol after addition of further controls, or statistical reassessment of raw data. 
 
Preliminary Findings Presentation of results from pilot studies which may establish a solid basis 
for further investigations. Format similar to original research report but with more emphasis in 
discussion of future studies and hypotheses arising from pilot study. 
 
Commentaries Include articles that do not fit into the above criteria as original research. Includes 
commentary and essays especially in regards to history, philosophy, professional, educational, 
clinical, ethical, political and legal aspects of osteopathic medicine. 
 
Clinical Practice Authors are encouraged to submit papers in one of the following formats: Case 
Report, Case Problem, and Evidence in Practice. 
 
Case Reports usually document the management of one patient, with an emphasis on 
presentations that are unusual, rare or where there was an unexpected response to treatment eg. 
an unexpected side effect or adverse reaction. Authors may also wish to present a case series 
where multiple occurrences of a similar phenomenon are documented. Preference will be given 
to reports that are prospective in their planning and utilise Single System Designs, including 
objective measures. 
 
The aim of the Case Problem is to provide a more thorough discussion of the differential 
diagnosis of a clinical problem. The emphasis is on the clinical reasoning and logic employed in 
the diagnostic process.  
 
The purpose of the Evidence in Practice report is to provide an account of the application of the 
recognised Evidence Based Medicine process to a real clinical problem. The paper should be 
written with reference to each of the following five steps: 1. Developing an answerable clinical 
question. 2. The processes employed in searching the literature for evidence. 3. The appraisal of 
evidence for usefulness and applicability. 4. Integrating the critical appraisal with existing 
clinical expertise and with the patient's unique biology, values, and circumstances. 5. Reflect on 
the process (steps 1-4), evaluating effectiveness, and identifying deficiencies. 
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Presentation of Typescripts  
 
Your article should be typed on A4 paper, double-spaced with margins of at least 3cm. Number 
all pages consecutively beginning with the title page. 
 
To facilitate anonymity, the author's names and any reference to their addresses should only 
appear on the title page. Please check your typescript carefully before you send it off, both for 
correct content and typographic errors. It is not possible to change the content of accepted 
typescripts during production. 
 
Papers should be set out as follows, with each section beginning on a separate page: 
 
Title page  
To facilitate the peer-review process, two title pages are required. The first should carry just the 
title of the paper and no information that might identify the author or institution. The second 
should contain the following information: title of paper; full name(s) and address(es) of author(s) 
clearly indicating who is the corresponding author; you should give a maximum of four 
degrees/qualifications for each author and the current relevant appointment only; institutional 
affiliation; name, address, telephone, fax and e-mail of the corresponding author; source(s) of 
support in the form of funding and/or equipment. 
 
Keywords  
Include three to ten keywords. These should be indexing terms that may be published with the 
abstract with the aim of increasing the likely accessibility of your paper to potential readers 
searching the literature. Therefore, ensure keywords are descriptive of the study. Refer to 
http://www.nlm.nih.gov/mesh/meshhome.html for the MeSH thesaurus. 
 
Abstract  
Both qualitative and quantitative research approaches should be accompanied by a structured 
abstract. Commentaries and Essays may continue to use text based abstracts of no more than 150 
words. All original articles should include the following headings in the abstract as 
appropriate: Background, Objective, Design, Setting, Methods, Subjects, Results, 
andConclusions. As an absolute minimum: Objectives, Methods, Results, and Conclusions must 
be provided for all original articles. Abstracts for reviews of the literature (in particular 
systematic reviews and meta-analysis) should include the following headings as 
appropriate: Objectives, Data Sources, Study Selection, Data Extraction, Data Synthesis, 
Conclusions. Abstracts for Case Studies should include the following headings as 
appropriate: Background, Objectives, Clinical Features, Intervention and Outcomes, 
Conclusions. 
 
Text  
The text of observational and experimental articles is usually, but not necessarily, divided into 
sections with the headings; introduction, methods, results, results and discussion. In longer 
articles, headings should be used only to enhance the readability. Three categories of headings 
should be used: 
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•major ones should be typed in capital letter in the centre of the page and underlined 
•secondary ones should be typed in lower case (with an initial capital letter) in the left hand 
margin and underlined 
•minor ones typed in lower case and italicised 
 
 
Do not use 'he', 'his' etc. here the sex of the person is unknown; say 'the patient' etc. Avoid 
inelegant alternatives such as 'he/she'. Avoid sexist language. 
 
Statement of Competing Interests  
When submitting a Research report you will need to consider if you, or any of your co-authors, 
are an Editor or Editorial Board member of the International Journal of Osteopathic Medicine. If 
this is the case you will need to include a section, at the end of your manuscript immediately 
before the reference section, called "Statement of Competing Interests". Example statement, 
which may require editing, is as follows: {Name of author} is an Editor of the Int J Osteopath 
Med; {Name of author} is a member of the Editorial Board of the Int J Osteopath Med but was 
not involved in review or editorial decisions regarding this manuscript. 
 
References  
Responsibility for the accuracy of bibliographic citations lies entirely with the Authors. 
 
Citations in the text: Please ensure that every reference cited in the text is also present in the 
reference list (and vice versa). Avoid using references in the abstract. Unpublished results and 
personal communications are not recommended in the reference list, but may be mentioned in 
the text. If these references are included in the reference list they should follow the standard 
reference style of the journal and should include a substitution of the publication date with either 
"Unpublished results" or "Personal communication" Citation of a reference as "in press" implies 
that the item has been accepted for publication. 
 
Text: Indicate references by superscript numbers in the text. The actual Authors can be referred 
to, but the reference number(s) must always be given. 
 
List: Number the references in the list in the order in which they appear in the text. 
 
Examples:  
 
Reference to a journal publication: 
 
1. Van der Geer J, Hanraads JAJ, Lupton RA. The art of writing a scientific article. J Sci 
Commun2000;163:51-9. 
 
Reference to a book: 
 
2. Strunk Jr W, White EB. The elements of style. 3rd ed. New York: Macmillan; 1979. 
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Reference to a chapter in an edited book: 
 
3. Mettam GR, Adams LB. How to prepare an electronic version of your article. In: Jones BS, 
Smith RZ, editors. Introduction to the electronic age. New York: E-Publishing Inc; 1999, p. 281-
304  
 
Note shortened form for last page number. e.g., 51-9, and that for more than 6 Authors the first 6 
should be listed followed by "et al." For further details you are referred to "Uniform 
Requirements for Manuscripts submitted to Biomedical Journals" (J Am Med Assoc 
1997;277:927-934) (see also  http://www.nejm.org/general/text/requirements/1.htm) 
 
Citing and listing of Web references. As a minimum, the full URL should be given. Any further 
information, if known (Author names, dates, reference to a source publication, etc.), should also 
be given. Web references can be listed separately (e.g., after the reference list) under a different 
heading if desired, or can be included in the reference list.  
 
Tables, Illustrations and Figures  
A detailed guide on electronic artwork is available on our website: 
http://www.elsevier.com/artworkinstructions  
 
Preparation of supplementary data. Elsevier accepts electronic supplementary material to 
support and enhance your scientific research. Supplementary files offer the author additional 
possibilities to publish supporting applications, movies, animation sequences, high-resolution 
images, background datasets, sound clips and more. Supplementary files supplied will be 
published online alongside the electronic version of your article in Elsevier Web products, 
including ScienceDirect:  http://www.sciencedirect.com. In order to ensure that your 
submitted material is directly usable, please ensure that data are provided in one of our 
recommended file formats. Authors should submit the material in electronic format together with 
the article and supply a concise and descriptive caption for each file. Video files: please supply 
'stills' with your files: you can choose any frame from the video or make a separate image. These 
will be used instead of standard icons and will personalize the link to your supplementary 
information. For more detailed instructions please visit our artwork instruction pages at 
 http://www.elsevier.com/artworkinstructions. 
 
Illustrations and tables that have appeared elsewhere must be accompanied by written 
permission to reproduce them from the original publishers. This is necessary even if you are an 
author of the borrowed material. Borrowed material should be acknowledged in the captions in 
the exact wording required by the copyright holder. If not specified, use this style: `Reproduced 
by kind permission of . . . (publishers) from . . . (reference).' Identifiable clinical photographs 
must be accompanied by written permission from the patient.  
 
The text of original research for a quantitative or qualitative study is typically subdivided into the 
following sections: 
 
Introduction  
State the purpose of the article. Summarize the rationale for the study or observation. Give only 
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strictly pertinent references and do not review the subject extensively. Do not include data or 
conclusions from the work being reported. 
 
Materials and Methods  
Describe your selection of observational or experimental subjects (including controls). Identify 
the methods, apparatus (manufacturer's name and address in parenthesis) and procedures in 
sufficient detail to allow workers to reproduce the results. Give references and brief descriptions 
for methods that have been published but are not well known; describe new methods and 
evaluate limitations. 
 
Indicate whether procedures followed were in accordance with the ethical standards of the 
institution or regional committee responsible for ethical standards. Do not use patient names or 
initials. Take care to mask the identity of any subjects in illustrative material. 
 
Results  
Present results in logical sequence in the text, tables and illustrations. Do not repeat in the text all 
the data in the tables or illustrations. Emphasise or summarise only important observations. 
 
Discussion  
Emphasise the new and important aspects of the study and the conclusions that follow from 
them. Do not repeat in detail data or other material given in the introduction or the results 
section. Include implications of the findings and their limitations, include implications for future 
research. Relate the observations to other relevant studies. Link the conclusion with the goals of 
the study, but avoid unqualified statements and conclusions not completely supported by your 
data. State new hypothesis when warranted, but clearly label them as such. Recommendations, 
when appropriate, may be included. 
 
Conflict of interest  
At the end of the text, under a subheading "Conflict of interest statement" all authors must 
disclose any financial and personal relationships with other people or organizations that could 
inappropriately influence (bias) their work. Examples of potential conflicts of interest include 
employment, consultancies, stock ownership, honoraria, paid expert testimony, patent 
applications/registrations, and grants or other funding. 
 
Ethical considerations  
Human subjects. Work on human beings that is submitted to The International Journal of 
Osteopathic Medicine should comply with the principles laid down in the declaration of 
Helsinki; Recommendations guiding physicians in biomedical research involving human 
subjects. Adopted by the 18th World Medical Assembly, Helsinki, Finland, June 1964, amended 
by the 29th World Medical Assembly, Tokyo, Japan, October 1975, the 35th World Medical 
Assembly, Venice, Italy, October 1983, and the 41st World Medical Assembly, Hong Kong, 
September 1989. The manuscript should contain a statement that has been approved by the 
appropriate ethical committees related to the institution(s) in which it was performed and that 
subjects gave informed consent to the work. Studies involving experiments with animals must 
state that their care was in accordance with institution guidelines. Patients' and volunteers' 
names, initials, and hospital numbers should not be used. In a case report, the subject's written 
107 
 
consent should be provided. It is the author's responsibility to ensure all appropriate consents 
have been obtained. 
 
Patient anonymity. Studies on patients or volunteers require ethics committee approval and 
informed consent which should be documented in your paper.  
 
Patients have a right to privacy. Therefore identifying information, including patients' images, 
names, initials, or hospital numbers, should not be included in videos, recordings, written 
descriptions, photographs, and pedigrees unless the information is essential for scientific 
purposes and you have obtained written informed consent for publication in print and electronic 
form from the patient (or parent, guardian or next of kin where applicable). If such consent is 
made subject to any conditions, Elsevier must be made aware of all such conditions. Written 
consents must be provided to Elsevier on request. 
 
Even where consent has been given, identifying details should be omitted if they are not 
essential. If identifying characteristics are altered to protect anonymity, such as in genetic 
pedigrees, authors should provide assurance that alterations do not distort scientific meaning and 
editors should so note. 
 
If such consent has not been obtained, personal details of patients included in any part of the 
paper and in any supplementary materials (including all illustrations and videos) must be 
removed before submission. 
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All manuscripts submitted to the journal should be accompanied by an Author Contribution 
Statement. The purpose of the Statement is to give appropriate credit to each author for their role 
in the study. All persons listed as authors should have made substantive intellectual contributions 
to the research. To qualify for authorship each person listed should have made contributions in 
each of the following; 
1) Contributions to conception and design; data acquisition; data analysis and interpretation; 
2) Drafting of manuscript, or critical revision for important intellectual content; 
3) All authors must have given approval to the final version of the manuscript submitted for 
consideration to publish. 
Acquisition of funding; provision of resources; data collection; or general supervision, alone, is 
not sufficient justification for authorship. Contributors who do not meet the criteria for 
authorship as outlined above should be listed in the Acknowledgements section. 
Acknowledgements may include contributions of technical assistance, proof reading and editing, 
or assistance with resources and funding. The statement may be published in the paper as 
108 
 
appropriate. 
Example of suggested format. Note the use of author initials. 
AB conceived the idea for the study. AB and CD contributed to the design and planning of the 
research. All authors were involved in data collection. AB and EF analysed the data. AB and CD 
wrote the first draft of the manuscript. EF coordinated funding for the project. All authors edited 
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Changes to authorship  
This policy concerns the addition, deletion, or rearrangement of author names in the authorship 
of accepted manuscripts: 
 
 
Before the accepted manuscript is published in an online issue: Requests to add or remove an 
author, or to rearrange the author names, must be sent to the Journal Manager from the 
corresponding author of the accepted manuscript and must include: (a) the reason the name 
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Page Proofs  
One set of page proofs will be sent by e-mail to the corresponding author (if we do not have an e-
mail address then paper proofs will be sent by post). Elsevier now sends PDF proofs which can 
be annotated, for this you will need to download Adobe Reader version 7 (or higher) available 
free from  http://www.adobe.com/products/acrobat/readstep2.html. Instructions on how to 
annotate PDF files will accompany the proofs. The exact system requirements are given at the 
Adobe site:  http://www.adobe.com/products/acrobat/acrrsystemreqs.html#70win.  
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